

CURRICULUM VITAE

Irwin H. Gelman, PhD

HOME ADDRESS

130 Windsor Avenue
Buffalo, New York 14209
Telephone: 716-883-4020
Mobile: 917-302-3296
Email: igelman1@adelphia.net

OFFICE ADDRESS

Roswell Park Cancer Institute
Department of Cancer Genetics
Elm and Carlton Streets
Buffalo, New York 14263
Telephone: 716-845-7681
FAX: 716-845-1698
Email: Irwin.Gelman@RoswellPark.org

CURRENT APPOINTMENT

Director of Research Integration
Roswell Park Cancer Institute

Professor and Chair
Department of Cancer Genetics, Genomics and Development
State University of New York at Buffalo

Director
Functional Genomic Screening Core Resource
Roswell Park Cancer Institute

EDUCATION

Hopkins High School
New Haven, Connecticut

1972-1976

Wesleyan University
Middletown, Connecticut

1980
Biochemistry BA

Columbia University
New York, New York

1983 - Microbiology MA
1985 - Microbiology MPhil
1987 - Microbiology PhD

POSTGRADUATE TRAINING

American Cancer Society Postdoctoral Associate
The Rockefeller University, New York, New York
Mentor: Dr. Hidesaburo Hanafusa

1987-1991

CURRENT APPOINTMENTS

Roswell Park Cancer Institute

Associate Member	2003 - 2008
Vice Chairman, Department of Cancer Genetics	2006 - 2008
Associate Professor of Oncology	2006 - 2008
Resource Director, RPCI-UB shRNA Core Facility	2006 – present
Professor of Oncology	2008 - 2016
Interim Chairman, Department of Cancer Genetics	2008 – 2010
John and Santa Palisano Chair, Department of Genetics	2010 – 2016
Leader, RPCI-CCSG Genetics Program	2010 – 2016
Chair, Cell and Molecular Biology Academic Program	2010 – present
Director, RPCI Genomics Shared Resource	2012 – 2014
Director of Research Integration, RPCI	2016 – present
Distinguished Member, RPCI	2016 – present

State University of New York at Buffalo

Associate Professor, Department of Cellular & Molecular Biology	2003 – 2008
Professor, Department of Cellular and Molecular Biology	2009 - present
Senior Member Graduate Faculty	2003 - present
Member, Graduate Faculty, Roswell Park Graduate Division	2003 – present
Member, Genetics, Genomics & Bioinformatics Graduate Program	2015 – present
Co-Director, Global Virus Network, SUNY-Buffalo Center of Excellence	2016 - present

Member, New York State Center of Excellence,
Bioinformatics & Life Sciences

2006 – present

Advisory Committee Member, UB Center for Integrated Global
Biomedical Sciences, Global Virus Network

2016 - present

Shenzhen Key Lab for Translational Medicine, China
Honorary Professorship

2012

PREVIOUS APPOINTMENTS

Columbia University

NIH Graduate Traineeship	1981 - 1982
NIH Graduate Teaching Fellowship	1982 - 1983
Graduate Research Fellow	1983 - 1987

The Rockefeller University

Postdoctoral Associate	1987 - 1990
------------------------	-------------

City University of New York

Biomedical Sciences Program - Doctoral Faculty	1991 - 1998
Physician Assistants Program - Microbiology Course Director	1992 - 2002
Adjunct Associate Professor, Department of Microbiology	1992 - 2002

National Medical School Board Review - Faculty

1993 - 1998

Mount Sinai School of Medicine

Assistant Professor of Microbiology

1990 - 1999

Member, Ruttenberg Cancer Center

1996 - 2003

Research Associate Professor, Ruttenberg Cancer Center

1999 - 2003

Associate Professor, Department of Medicine

2000 - 2003

RESEARCH EXPERIENCE

1975-1976 under Dr. G. Osbaldiston, Dept. of Animal Sciences, Yale University, Investigations of Iron Overload Anemias in Inbred Basenji Dogs.

1977-1980 under Dr. W. Firshein, Department of Biology, Wesleyan University, Studies on DNA-Membrane Complexes in Pneumococcus.

1980-1981 under Dr. M. Young, Dept. of Genetics, The Rockefeller University, Studies on Transposable Elements in Drosophila.

1981-1987 under Dr. S. Silverstein, Department of Microbiology, Columbia University, Control of Herpes Simplex Virus Gene Regulation (Doctoral Thesis).

1987-1990 under Dr. H. Hanafusa, Dept. of Molecular Oncology, The Rockefeller University, Suppression and Regression of SRC-Induced Tumors.

1991-2000 Department of Microbiology, Mount Sinai Medical Center: (1) Tumor suppression via the control of cytoskeletal architecture and cell signaling; (2) Involvement of src-family and focal adhesion kinases in mitogen- and integrin-induced signaling; (3) Novel lenti- and retroviruses in Kaposi's Sarcoma and Chronic Fatigue Syndrome.

2000-2003 Department of Medicine, Division of Infectious Diseases: (1) Tumor suppression and mitogenic control through the kinase scaffolding functions of the major PKC substrate, SSeCKS; (2) Involvement of src-family and focal adhesion kinases in mitogen- and integrin-induced signaling; (3) Identification and characterization of a novel EGF/PDGF-induced, FAK-dependent tyrosine kinase involved in cytoskeletal reorganization

RECOGNITION, HONORS AND AWARDS

High Honors in Biology- Wesleyan University

1980

NIH Postdoctoral Fellowship (declined)

1987

American Cancer Society Postdoctoral Fellowship

1987 - 1990

American Foundation for AIDS Research Scholars Award

1991 - 1992/1992 -1993

Section Co-Chairman, AACR Annual Meeting

1995

CaP CURE Award

1998

Excellence in Teaching Award, Mount Sinai School of Medicine

1999 - 2000

Shannon Award, NIH-NCI

2001 - 2003

Visiting Professor, Nagoya University

Sept. 2004

Invited presenter, 10 th Prouts Neck Meeting on Prostate Cancer	2004
Invited presenter, 11 th Prouts Neck Meeting on Prostate Cancer	2006
Invited presenter, Department of Defense IMPaCT Meeting, Atlanta, GA	2007
Profiled in RPCI Roswellness, "Preventing Cancer", Fall issue	2008
Profiled, RPCI-Alumni Journal, "The Voice of My Ancestors"	2009
Reappointment with Distinction, University at Buffalo Graduate Faculty	2014

TEACHING EXPERIENCE

Teaching Assistant Med. Microbiol. Columbia School of Physicians and Surgeons	1981 - 1982
Tutor in Bacteriology, Virology and Immunology, Columbia Phys. and Surgeons	1981 - 1984
Lecturer in Basic & Transplantation Immunology Bronx-Lebanon Hospital	1983 - 1990
Lecturer in Medical Microbiology, Mount Sinai School of Medicine	1990 - 2003
Lecturer in Molecular Biology CORE I, Mount Sinai School of Medicine	1994 - 1998
Lecturer in Animal Virology, Mount Sinai School of Medicine	1992 - 2003
Course Director, Microbiology, CUNY Med. School P.A. Program	1992 - 2002
Lecturer in Virology, National Medical School Board Review	1993 - 1998
Lecturer, Viral Immunology, American In Vitro Allergy/Immunology Society	1994
Lecturer, Molecular Basis of Disease, Mount Sinai School of Medicine	2000 - 2003
Lecturer, AIDS and HIV, Mount Sinai School of Medicine	2000 - 2003
Lecturer, Surgical Oncology, Roswell Park Cancer Institute	2003 - present
Lecturer, Cellular and Molecular Biology, State University of New York at Buffalo	2003 - present
Lecturer, BPR 577: Tools and Models for Molecular Oncology	2008 - present
Lecturer, Cancer Genetics in CanSys Program, Luxembourg	2010 - present
Lecturer, RPN530: Oncology for Scientists, Viral Carcinogenesis	2013 - present
Lecturer, Student/postdoc Mentoring Program: Scientific Collaboration, Effective Interviewing, Effective Grant Writing	2015 - present
Lecturer, RPN 541, Scientific Collaborations: Roles, Challenges and Pressures in Academia and Industry	2017 -

PROFESSIONAL SOCIETIES

American Society for Biochemistry and Molecular Biology
 American Society for Cell Biology
 American Society for Matrix Biology
 American Association for the Advancement of Science
 American Association for Cancer Research
 American Society for Microbiology
 American Society for Virology
 CUNY Academy of Humanities and Science
 Metastasis Research Society
 New York State Academy of Science

INDUSTRY EXPERIENCE

Co-founder and founding stockholder of Antigenics, Inc., now Agenus (NASDAQ: AGEN), a biotech company producing immunotherapies for cancer and infectious diseases based on immunization with endogenous heat-shock proteins loaded with priming immunogens.

Consultant to Anatomical Travelogue, Inc., a company specializing in producing 3-D digitized images of organs systems, tissues and cells for the scientific and lay media communities.

Scientific Advisory Board, Kinex (now Athenex) Pharmaceuticals LLC, Buffalo, NY. Responsible for the development of KX2-391 and KX2-361, dual Src-kinase and tubulin inhibitors currently in Phase II/III clinical trials worldwide.

Consultant, Gerson Lehman Group; topics- RNAi, therapeutic targeting of Src Kinases, cancer metastasis genes

Consultant, Defined Health; topics- RNAi, therapeutic targeting of Src Kinases, cancer metastases genes

MEDIA EXPERIENCE

Live and taped interviews with local television (New York: WABC, WNBC, WCBS; Buffalo: WIVB, WGRZ) and radio (WCBS, WBEN), National television (NBC, ABC-Nightline), international television (CBC) on various aspects of cancer, infectious diseases such as AIDS, bioterrorism, anthrax and smallpox.

Interviews with print media (New York Times, Wall Street Journal, USA Today, Buffalo News) on various aspects of cancer, infectious diseases such as AIDS, bioterrorism, anthrax and smallpox.

Quoted in SciBX Science Business Exchange, "The root of prostate cancer" Martz, L., *SciBX*, **3**(33); doi:10.1038/scibx.2010.1000 (<http://www.nature.com/scibx/journal/v3/n33/full/scibx.2010.1000.html>).

Interviewed for *Buffalo News*, *Buffalo ArtVoice*, *Buffalo Spree*, *Buffalo Business First*, WGRZ, WIBV (http://www.cw23.com/dpp/winging_it/raising-money-to-cure-cancer).

ACADEMIC and ADMINISTRATIVE EXPERIENCE - Mount Sinai School of Medicine

Member, Mount Sinai Graduate School Admissions Committee

Member, Mount Sinai Medical Science Training Program Admissions Committee

Chairman, Department of Microbiology Admissions Committee

Chairman, Department of Microbiology Graduate Student Committee

Departmental Representative, Dean's Lecture Series Committee

Member, Departmental Graduate Curriculum Committee

Acting Course Director, Medical Microbiology Course, 1992-1993

Departmental Representative, Faculty Council

Member, Ad Hoc Curriculum Committee

Faculty Member, Cell and Molecular Sciences Training Program

Member, Steering Committee, Cell & Molecular Sciences Training Program

Member, Mount Sinai AIDS Malignancy Consortium

Faculty Member, Molecular Basis of Disease Training Program

Member, Diagnostics and CORE Facilities Subcommittee

Member, MSSM Prostate Cancer Working Group

Assistant Director, Research and Instrumentation, Department of Medicine

Member, Space Committee, Department of Medicine

COMMITTEES: INSTITUTE

Member, Technology Transfer Committee

2003 - 2006

Member, Proteomics/Biopolymer Resource Steering Committee

2003 - 2007

Member, Internal Biosafety Committee

2007 - 2008

Member, Translational Research Group – Urologic Oncology

2003 - present

Member, Cancer Center Support Grant - Genetics Program	2003 - present
Member, Cancer Center Support Grant - Genetics Program - Internal Advisory Board	2003 - present
Member, Cancer Center Support Grant – Steering Committee	2007 - 2016
Member, Biostatistics Resource Advisory Committee	2003 - present
Member, Internet/Intranet Oversight Committee	2004 - 2016
Member, Genitourinary Advisory Committee	2004 - present
Member, Alliance Foundation Scientific Advisory Committee	2004 - present
Member, American Cancer Society Scientific Advisory Committee	2004 - present
Member, Baldrige Committee on Organizational Excellence	2007 - 2014
Member, Scientific Leadership Council Committee	2007 - 2016
Member, Senior Strategy Group Committee	2007 - 2016
Member, Tissue Utilization Committee	2007 - 2012
Member, Tactical Working Group- Microenvironment and New Drug	2008 - 2012
Member, CCSG Steering Committee	2008 - 2016
Member, Pathology Resource Network (PRN)	2008 - 2016
Member, Mouse Tumor Models Resource Advisory Committee	2008 - present
Member, Grant Management Task Force Core Team	2008 - 2016
Chairman, Proteomics/Biopolymer Resource Steering Committee	2008 - 2012
Interim Program Leader, CCSG Genetics Program	2008 – 2010
Member, Alliance Foundation Clinical Advisory Committee	2008 – present
Program co-Leader, CCSG MEFG Program	2010 – 2011
Program Leader, CCSG Genetics Program	2010 – 2016
Member, Project Cancer Education Steering Committee	2011 – 2017
Co-Leader, RPCI Grant Review Committee	2012 – present
Chair, RPCI Internal Biosafety Committee	2013 – 2015
Chair, RPCI Shared Genomics Core Advisory Committee	2014 – present
Member, Faculty Development Committee	2016 – present
Member, RPCI Science Retreat Committee	2015 – 2017
Chair, RPCI Science Retreat Committee	2017 – present
Member, Roswell Academic Integrity Adjudication Committee	2019 - present

COMMITTEES: UNIVERSITY/EDUCATION

Senior Member Graduate Faculty, State University of New York at Buffalo	2003 - present
Member, Graduate Faculty, Roswell Park Graduate Division State University of New York at Buffalo	2003 - present
Member, New York State Center of Excellence, Bioinformatics & Life Sciences State University of New York at Buffalo	2006 – present
Member, RPCI Graduate Program Roundtable	2011 – 2014
Member, UB-RPCI Graduate Divisional Committee	2011 - present

SEARCH COMMITTEES- Roswell Park Cancer Institute

Member, Department of Medicine Chair	2005 - 2007
Member, Biophysical Therapy/ Cell Stress Biology Chair	2005 - 2007
Member, Pharmacology and Therapeutics Chair	2005 - 2007
Member, Graduate Education Dean Search Committee	2010 – present
Member, Pediatrics Chair Search Committee	2014 – present

Member, Pharmacology and Therapeutics Chair
Member, Urology Clinical and Research Leaders

2015 – 2016
2015 - present

FACULTY MENTORING- RPCI

Andrei Bakin, Ph.D., Assistant Member
Yurij Ionov, Ph.D., Assoc. Member
Dominic Smiraglia, Ph.D., Assistant Member
Yuejin Yu, Ph.D., Assoc. Member
Warren Graham, MD, Asst. Member, Medicine; now at Medical University of South Carolina
Scott Abrams, Ph.D., Assoc. Member, Immunology
Jianmin, Zhang, Ph.D., Asst. Member, Cancer Genetics
Leigh Ellis, Ph.D., Asst. Member, Pharmacology and Therapeutics
Hannalore Hemmers, Ph.D., Asst. Member, Urology and Cancer Genetics, now at Cleveland Clinic
John Ebos, Ph.D., Asst. Member, Medicine and Cancer Genetics

EDITORIAL BOARDS

Virology - Associate Editor (1998-2004)
Frontiers in Bioscience - Associate Editor (2002-2008)
Viral Immunology - Assistant Editor (1996-1999)
Biomedical PDA (biomedical software development company for Palm) and Contributing Editor.
Gene and Cancer- Guest co-Editor (with M. Sudol), Hanafusa Memorial Issue, Parts 1 and 2, Nov. and Dec. 2010.
International Journal of Biological Sciences- Editorial Board Member, special issue: “Biological and Clinical Significance of Androgen Receptor in Prostate Cancer” 2013
Cancer Research- Editorial Board Member, 2013- present
Journal of Cancer Biology & Research – Associate Editor, 2013- present
Oncogene- Receiving Editor, 2015- present

AD HOC REVIEWER

American Journal of Physiology, BioTechniques, BMC Cancer, BMC Gastroenterology, British Journal of Hematology, British Journal of Pharmacology, Cancer Cell, Cancer Research, Carcinogenesis, Cell and Tissue Research, Experimental Cell Research, Expert Opinion on Therapeutic Patents, Journal of Biological Chemistry, Journal of Cell Science, Journal of Molecular Signaling, Journal of Vascular Research, Molecular Biology of the Cell, Molecular and Cellular Biology, Nature Cell Biology, Neuroscience, Protein Engineering, Oncogene, Oncotarget, PLoS ONE, Urology.

SCIENTIFIC ADVISORY BOARDS

Alliance Foundation, Research Grant Reviewer 2004 – Present
Israel Cancer Fund Grant Reviewer 2008 - 2010
Healthcare Security & Emergency Management (previously, Bioterror Medical Alert)
Hong Kong Cancer Fund - Ad Hoc Reviewer 2006
American Cancer Society Institutional Research Grant Committee
Roswell Park Cancer Institute, Grant Reviewer 2005 - present

March of Dimes- Ad Hoc Reviewer	2009
National Functional Genomics Center, Scientific Advisory Committee, Board of Directors- Metastasis Research Society	2010 – present 2015-2018
Leader, Outreach II Working Group, Metastasis Research Society	2015 – present
Moffitt Cancer Center P01 External Advisory Board	2018 - present

STUDY SECTIONS

Ad Hoc Member, NIH AIDS Malignancy Study Section	1999
Ad Hoc Member, NIH Metabolic Pathology Study Section	2001
Ad Hoc Member, NIH Pathology C SEP Study Section	2001, 2003, 2004
Ad Hoc Member, NIH CAMP SEP Study Section	2003, 2004
Ad Hoc Member, NIH CAMP Study Section	2004 - 2008
Ad Hoc Member, ZRG1 ONC-K (03) SEP Study Section	2008
Ad Hoc Member, CFIDS Association Study Section	2008
Ad Hoc Member, New Jersey Comm. Science & Technology, Stem Cells	2008
Member, NIH ZRG1 Oncological Sciences Study Section	2001-2003
Member, NIH Tumor Microenvironment (TME) Study Section	2003-2004
Member, DOD PCRP, Cell Biology Study Section, CBY-2	2004
Member, DOD BCRP, Cell Biology Study Section, CBY-1	2005
Member, DOD PCRP, Cell Biology Study Section, CBY-3	2006
Member, DOD CDMRP, Breast Cancer Concept Award Study Section	2006, 2007, 2008
Member, DOD PCRP, Programmatic Integration Panel	2008, 2009
Member, Israel Cancer Research Fund, Grant Review Panel	2008, 2009, 2010
Member, Special Emphasis Panel, "Provocative Questions" 05 ZCA1 SRLB-D	2005
Ad Hoc Member, Czech Science Foundation Grant Review Agency	2012
Member, DOD PCRP, Pathobiology Study Section, PBY-2	2012
Ad Hoc Grant Reviewer, Prostate Cancer UK	2013
Ad Hoc Grant Reviewer, Israel Science Foundation	2013-
Ad Hoc Grant Reviewer, Prostate Cancer Canada	2015-
Member, DOD BCRP, Pathobiology Study Section, PBY-2	2014
Member, NCCN Site Review Panel, U. Minn. Cancer Center	2018
Ad Hoc Grant Reviewer, DOD PRCRP Horizon Award Study Section	2018
Ad Hoc Grant Reviewer, Siteman Cancer Center, WUSTL	2019

PATENTS

- Patent #5,478,724 - Lentivirus-Specific Nucleotide Probes and Methods of Use
Drs. Stephen S. Morse, Irwin H. Gelman, and Hidesaburo Hanafusa
Filing date: 10/29/93 Granted: 12/26/95
- Patent #5,910,442- Tumor Suppressor Gene
Dr. Irwin H. Gelman
Filing date: 6/18/96 Granted: 6/8/99
- Patent #6,582,956 Tumor Suppressor Gene
Dr. Irwin H. Geman
Filing date: 11/25/97 Granted: 6/24/03.

MEETINGS ORGANIZED

May 7, 1997	The Discovery of Oncogenes: Crossroads to the Future (Memorial Symposium for Teruko Hanafusa) The Rockefeller University Raised \$27,000 for one-day event from private and public sources (including NIH grant R13-CA75132 for \$5,000).
May 10-12, 2000	Co-Organizer - Tyrosine Phosphorylation in Signal Transduction Osaka, Japan
November 16-20, 2004	Co-Organizer - The Oncogene Revolution, Osaka, Japan
July 28-30, 2005	Co-Organizer - Prostate Cancer: Roadmap to the Future, Roswell Park Cancer Institute, Buffalo, NY
September 16-21, 2016	Co-Organizer- Metastasis Research Society Biennial Meeting, Chengdu, China
June 22-23, 2018	Co-Organizer, Metastatic Breast Cancer Engagement Conference, Tampa, FL
July 9-10, 2018	Chair, Organizing Committee, Roswell Park Comprehensive Cancer Center Annual Science Retreat
August 1-5, 2018	Co-Organizer, Metastasis Research Society Biennial Meeting, Princeton, NJ
June 6-8, 2019	Co-Organizer, Patient-Centered Outcomes Research Institute/Metastasis Research Society Metastatic Patient Engagement Conference II, Univ. of North Carolina.

COMMUNITY SERVICE

President, Holocaust Resource Center of Buffalo	2006 - 2008
Member, Hillel of Buffalo, Board of Directors	2006 - 2016
Member, Buffalo Jewish Federation Board of Governors	2006 - 2008
Member, Network of Religious Communities of Buffalo	2008 - present
Member, Cantors Assembly of the United Synagogue of Conservative Judaism	1998 - present
Roswell Park Alliance Foundation – Liaison for Cancer Genetics Department, various tours with community Leaders	
Member, Jewish Community Center Board of Directors	2014 - present

ACTIVE GRANT SUPPORT

Project Number: No number assigned (HRI #)
Source: Roswell Park Alliance Foundation
Title of Project: Strengthening knowledge for future generations: Cancer bio-banks in the landscapes of the Haudenosaunee.
Dates / % Effort: 1/1/18 - 12/31/19
Amount: \$100,000 (year/TDC)
Role: co-Investigator (R. Haring- PI)

Project Number: 1 R01-NH202337-01A1
Source: National Human Genome Institute
Title of Project: Preventing breast cancer metastasis by interrupting pathological exosomal crosstalk
Dates / % Effort: 9/1/17-8/31/22 10%
Amount: \$1,250,000 (TDC)
Role: co-Principal Investigator (with Juliane Nguyen, SUNY-Buffalo)

Project Number: No number assigned (HRI #)
Source: Roswell Park Alliance Foundation
Title of Project: Gene Essentialities in Fusion Oncogene-Driven Pediatric Sarcomas.
Dates / % Effort: 1/1/19 - 12/31/19
Amount: \$100,000 (year/TDC)
Role: PI

Project Number: 1R21CA235092-01A1
Source: National Cancer Institute
Title of Project: Drug Susceptibilities in Fusion Oncogene-Driven Pediatric Sarcomas
Dates / % Effort: 7/1/2019 – 6/30/2021 20%
Amount: \$275,000 (year/TDC)
Role: PI

PENDING GRANT APPLICATIONS

Project Number: No project number
Source: Prostate Cancer Foundation
Title of Project: β -Adrenergic receptor antagonists to prevent metastatic prostate cancer progression
Dates / % Effort: 2/1/20 – 1/31/23 10%
Amount: \$1,000,000 (TDC)
Role: co-Investigator (Repasky-PI)

Project Number: No project number
Source: American Cancer Society
Title of Project: Institutional Research Grant
Dates / % Effort: 2/1/20 – 1/31/25 5%
Amount: \$60,000 (TDC)
Role: PI

COMPLETED GRANT SUPPORT

Project Number: PC131811
Source: Department of Defense- CDMRP Prostate Cancer Research Program
Title of Project: Roswell Park Cancer Institute/Howard University Prostate Cancer Scholars Program (PI: Wendy Huss, RPCI)
Dates / % Effort: 9/1/2014 - 8/31/2017
Amount: \$185,000 (TDC)
Role: Mentor

Project Number: No number assigned (HRI #)
Source: Roswell Park Alliance Foundation
Title of Project: Identification of Gene Signatures that Drive Early vs. Late Prostate Cancer
Dates / % Effort: 12/1/15 - 11/30/17
Amount: \$50,000 (year/TDC)
Role: Principal Investigator

Project Number: No number assigned (HRI #)
Source: Roswell Park Alliance Foundation
Title of Project: Identification and characterization of genes regulating breast cancer dormancy in 3D bone niche cultures
Dates / % Effort: 5/01/16 – 4/31/17
Amount: \$100,000 (year/TDC)
Role: Principal Investigator

Project Number: W81XWH-14-1-0395/PC131499
Source: Department of Defense- CDMRP Prostate Cancer Research Program
Title of Project: Mechanisms to target AR-driven resistance to CYP17A1 inhibitors
Dates / % Effort: 9/1/2014 - 8/31/2016
Amount: \$135,000 (TDC)
Role: Principal Investigator

Project Number: No number assigned (HRI #)
Source: Roswell Park Alliance Foundation
Title of Project: Novel breast cancer enhancer maps identified by STARR-seq
Dates / % Effort: 5/01/14 – 4/31/16
Amount: \$50,000 (year/TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: Kinex Pharmaceuticals, LLC

Title of Project: Using KXO1 to compare Immunocompetent and Immunodeficient
Dates / % Effort: 3/1/10-2/28/16 1%
Amount: \$58,000 (TDC)
Role: Principal Investigator

Project Number: W81XWH-11-2-0033
Source: Department of Defense TATRC, Advanced Cancer Genomics Institute
Title of Project: Genetic Signatures and Therapeutic Targets in Cancer Progression
Dates / % Effort: 1/1/2011-12/31/2013 10%
Amount: \$2,695,672 (TDC)
Role: Principal Investigator

Project Number: 2RO1 CA094108-16A1
Source: National Cancer Institute
Title of Project: PKA/PKC Regulation in Prostate Cancer by SSeCKS/Gravin/AKAP12
Dates / % Effort: 4/1/10-1/31/15 20%
Amount: \$852,300 (TDC)
Role: Principal Investigator

Project Number: No number assigned (HRI #)
Source: Roswell Park Alliance Foundation-Wilmot Cancer Center
Title of Project: Genetics of Progression of Barrett's Esophagus
Co-Investigators: M. Schiff, H. Nava, C. Morrison, J. Godfrey (Wilmot), D. Wang (Wilmot)
Dates / % Effort: 4/01/11 – 12/31/13
Amount: \$50,000 (year/TDC)
Role: Principal Investigator

Project Number: W81XWH-11-10116 (PC101210)
Source: Department of Defense
Experimental Hypothesis Development Award
Title of Project: Identification of Androgen Receptor Regulated Genes in Castration-
Recurrent Prostate Cancer
Dates / % Effort: 9/1/11-8/31/12 5%
Amount: \$75,000 (TDC)
Role: Principal Investigator

Project Number: W81XWH-08-1-0026
Source: Department of Defense, Prostate Cancer Program Synergistic Award
Title of Project: Dependency on Src-family kinases for recurrence of androgen-
independent prostate cancer
Co-Investigators: J. Mohler and G. Smith
Dates / % Effort: 7/15/08 – 7/14/11 10% (1-year NCE)
Amount: \$1,832,749 (TDC)
Role: Principal Investigator

Project Number: No number assigned (HRI #)
Source: Roswell Park Alliance Foundation
Title of Project: Genetic Signature for the Malignant Progression of Barrett's Esophagus
Co-Investigators: E. Kandel, M. Schiff, H. Nava, C. Morrison, C. LeVea, K. Moysich, S. Gill, D. Gold
Dates / % Effort: 1/01/10 – 12/31/10
Amount: \$150,000 (year/TDC)
Role: Principal Investigator

Project Number: 1RO1 CA116430 (Singh*)
Source: National Cancer Institute
Title of Project: Loss of FLJ13639 Expression in Acute Leukemia
Dates / % Effort: 9/16/06-7/31/11 5%
Amount: \$866,912 (TDC)
Role: Co-Investigator

Project Number: BC086529
Source: Department of Defense
Breast Cancer Research Program Concept Award,
Title of Project: Identification of Novel Breast Cancer Metastasis-Suppressor Genes
Dates / % Effort: 9/1/09 – 8/31/10 5%
Amount: \$75,000 (TDC)
Role: Principal Investigator

Project Number: No number assigned (HRI # 53-2512)
Source: Kinex Pharmaceuticals, LLC
Title of Project: Study various molecular mechanisms of KXO1
Dates / % Effort: 4/14/08-10/13/08
Amount: \$7,500 (TDC)
Role: Principal Investigator

Project Number: No number assigned (HRI # 62-2421)
Source: Roswell Park Alliance Foundation
Title of Project: Prostate Cancer Spore: Project 5 – Androgen receptor hypersensitization
Project Director: James Mohler, MD
Co-Investigator: Gary Smith, PhD
Dates / % Effort: 4/1/08-3/31/09 5%
Amount: \$10,000 (year/TDC)
Role: Principal Investigator

Project Number: R01 CA095429 (HRI # 55-0825)
Source: National Cancer Institute
Title of Project: Role of SMRT down-regulation in NHL transformation
Dates / % Effort: 4/1/03-3/31/09 5%
Amount: \$173,817 (year/TDC)
Role: Principal Investigator (assumed after the death of Lionel Coignet)

Project Number: W81XWH 07-1-0184
Source: Department of Defense, CDMRP- Prostate Hypothesis/Exploration Award
Title of Project: Identification of prostate cancer metastasis suppressor genes using genomic shRNA libraries
Dates: 2/1/07-7/31/08
Amount: \$75,000 (TDC)
Role: Principal Investigator

Project Number: No number assigned (HRI # 62-2405)
Source: Roswell Park Alliance Foundation
Title of Project: Therapeutic targeting Src-family kinases in post-castration recurrent prostate cancer
Co-Investigators: G. Smith, Collaborator: W. Huss
Dates / % Effort: 1/01/08 – 12/31/08
Amount: \$100,000 (year/TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: Roswell Park Alliance Foundation
Title of Project: Genome-wide shRNA library and virus vector resource for cancer gene discovery
Dates: 10/1/05 – 7/31/08
Amount: \$90,000 (TDC)
Role: Principal Investigator

Project Number: R01 CA94108
Source: National Cancer Institute
Title of Project: PKC/PKA regulation in prostate cancer by SSeCKS/ Gravin/AKAP12
Dates: 8/1/02 -6/30/08
Amount: \$763,822 (TDC)
Role: Principal Investigator

Fellowship: Adam Kisailus, PhD Postdoctoral Fellow
Project Number: 06A025
Source: American Institute for Cancer Research
Title of Project: Direct inhibitory effect of garcinol on FAK-mediated cancer cell survival
Dates: 07/01/06 – 06/30/08
Amount: \$28,000 (TDC)
Role: Mentor

Project Number: R01 HL70077
Source: National Institute of Health/NHLI
Title of Project: Analysis of a retinoid-induced tumor suppressor in SMC
Joseph Miano, PhD (University of Rochester)
Dates: 7/1/03 – 6/30/08

Amount: \$1,758,675 (TDC)
Role: Collaborator – RPCI Consortium

Project Number: W81XWH-04-1-0893
Source: Department of Defense, Prostate Cancer Research Program Hypothesis/Exploration Award
Title of Project: High throughput screen to identify novel inhibitors of prostate cancer metastasis
Dates: 10/1/04-9/30/07
Amount: \$375,000 (TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: Kinex Pharmaceuticals, LLC
Title of Project: Inhibition of SRC activity and induction of apoptosis in vivo by KX2-391
Dates: 7/1/06-9/1/06
Amount: \$6,510 (TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: Kinex Pharmaceuticals, LLC
Title of Project: Molecular characterization of SRC inhibitors KXL 329
Dates: 5/16/05-5/14/06
Amount: \$4,210 (TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: Kinex Pharmaceuticals, LLC
Title of Project: LX2-377 and -94 on jove cells
Dates: 4/1/06-4/24/06
Amount: \$2,730 (TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: Kinex Pharmaceuticals, LLC
Title of Project: Molecular characterization of SRC inhibitors
Dates: 4/18/05-4/17/06
Amount: \$3,360 (TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: Kinex Pharmaceuticals, LLC
Title of Project: HT29 and Jove: Lysates for kinexus
Dates: \$812 (TDC)
Amount: 4/1/06-4/14/06
Role: Principal Investigator

Project Number: No number assigned
Source: Kinex Pharmaceuticals, LLC
Title of Project: Signal pathways controlled by KD2-391, -392 and -394
Dates: 2/14/06-3/14/06
Amount: \$2,730 (TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: Kinex Pharmaceuticals, LLC
Title of Project: SRC signaling assays, KX2-329 vs. 328, 364 in 3T3/C SRC527F and SYF/R-SRC 527F
Dates: 12/1/05-2/1/06
Amount: \$5,040 (TDC)
Role: Principal Investigator

Project Number: 2R01 I45343
Source: National Institute of Health/NIAID
Title of Project: Induction of apoptosis by HIV-1 infected monocytic cells
Principal Investigator: Kirk Sperber, M.D.
Dates: 4/15/04-3/31/06
Amount: \$1,638,705 (TDC)
Role: Co- Investigator

Project Number: No number assigned
Source: Roswell Park Alliance Foundation
Title of Project: Identification and Characterization of Novel FAK Substrates Involved In Metastasis
Dates: 9/15/03-9/14/05
Amount: \$30,000 (TDC)
Role: Principal Investigator

Principal Investigator: Paul Klotman, M.D.
Project Number: P01DK56492-P02
Source: NIH/NIDDK
Title of Project: Pathogenesis of HIV-Associated Nephropathy
Dates: 7/1/99-6/30/03
Amount: \$3,724,369 (TDC)
Role: Co-Investigator

Project Number: No number assigned
Source: Cyclacel, Ltd
Title of Project: Preclinical Testing of CYC202 in A Murine Model of HIV-1-Induced Nephropathy
Dates: 7/1/02 - 6/30/03
Amount: \$145,000 (TDC)
Role: Principal Investigator

Fellowship: Peter J. Nelson, M.D.
Project Number: No number assigned
Source: National Kidney Foundation, Postdoctoral Research Fellowship
Title of Project: Targeting Cell Cycle Progression in HIV Nephropathy
Dates: 7/1/01-6/30/03
Amount: \$64,000 (TDC)
Role: Sponsor

Project Number: 1 R55 CA94108-01
Source: NIH/NCI Shannon Award
Title of Project: PKC/PKA Scaffolding by SSeCKS/Gravin/AKAP12
Dates: 12/01/01-7/31/02
Amount: \$100,000 (TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: Ruttenberg Cancer Center
Title of Project: Development Award
Dates: 2001-2002
Amount: 25,000 (TDC)
Role: Principal Investigator

Project Number: PC970115
Source: Department of Defense, U.S. Army Medical Research and Materiel Command Prostate Cancer Initiative
Title of Project: A Novel Diagnostic and Therapeutic Marker for Prostate Cancer
Dates: 1999-2000
Amount: \$286,660 (TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: Centers for Disease Control and Prevention
Title of Project: Abnormal Endogenous Virus Expression in Chronic Fatigue Syndrome
Dates: 1999-2000
Amount: \$33,750 (TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: CaPCURE Foundation
Title of Project: Novel Therapeutic and Diagnostic Target in Prostate Cancer
Dates: 1998-1999
Amount: \$75,000 (TDC)
Role: Principal Investigator

Project Number: R29-CA65787
Source: National Cancer Institute, NIH

Title of Project: Minority Graduate Student Supplement - Fellow- Jesus Vargas, Jr
Dates: 1996-2000
Amount: \$204,698 (TDC)
Role: Principal Investigator - Sponsor

Project Number: R29-CA65787
Source: National Cancer Institute, NIH
Title of Project: Characterization of a Novel Mitogenic Regulatory Gene
Dates: 1995-2000
Amount: \$575,750 (TDC)
Role: Principal Investigator

Project Number: #J7-6371
Source: The CFIDS Association of America, Inc.
Title of Project: Blinded Pilot Study of Endogenous Retrovirus Marker with Chronic Fatigue Syndrome
Dates: 1994-1995
Amount: \$2,000 (TDC)
Role: Principal Investigator

Project Number: #J7-6261
Source: Total Pharmaceutical Care
Title of Project: Expression of Endogenous Virus Sequences in Chronic Fatigue Syndrome
Dates: 1994-1995
Amount: \$30,000 (TDC)
Role: Principal Investigator

Project Number: (AmFAR) Scholars Award #001679-13-RGR
Source: American Foundation for AIDS Research
Title of Project: Novel Lentiviruses in Kaposi's Sarcoma
Dates: 1992-1993
Amount: \$60,000 (TDC)
Role: Principal Investigator

Project Number: No number assigned
Source: American Federation for AIDS Research (AmFAR)
Title of Project: Novel Lentiviruses in Kaposi's Sarcoma
Dates: 1991-1992
Amount: \$60,000 (TDC)
Role: Principal Investigator

PUBLICATIONS IN PEER REVIEWED JOURNALS

1. Zerial, A., **Gelman, I.**, Firshein, W. Glycolipids stimulate DNA polymerase activity in a DNA-membrane fraction and in a partially purified polymerase system extracted from pneumococcus. *J Bact* 135:78-85, 1978.

2. Firshein, W., **Gelman, I.** Enrichment of DNA polymerase III in a DNA-Membrane complex purified from pneumococcus: the possible existence of subcomplexes. *Mol Gen Genet* 182:87-96, 1981.
3. **Gelman, I.H.** and Silverstein, S. Identification of immediate early genes from herpes simplex virus that transactivate the virus thymidine kinase gene. *Proc Natl Acad Sci* 82:5265-5269, 1985.
4. **Gelman, I.H.** and Silverstein, S. Coordinate regulation of herpes simplex virus gene expression is mediated by the functional interaction of two immediate early gene products. *J Mol Biol* 191:395-409, 1986.
5. **Gelman, I.H.** and Silverstein, S. Herpes simplex virus immediate-early promoters are responsive to virus and cell trans-acting factors. *J Virol* 61:2286-2296, 1987.
6. **Gelman, I.H.**, Silverstein, S. Dissection of immediate-early gene promoters from herpes simplex virus: sequences that respond to the virus transcriptional activators. *J Virol* 61:3167-3172, 1987.
7. **Gelman, I.H.**, and Hanafusa, H. Suppression of rous sarcoma virus-induced tumor formation by preinfection with viruses encoding src protein with novel n-termini. *J Virol* 63:2461-2468, 1989.
8. Kemp, L.M., **Gelman, I.H.**, Silverstein S.J., Latchman, D.S. Regulation of HSV immediate-early promoters in mouse neuroblastoma cells. *Neurosci Lett* 118:185, 1990.
9. **Gelman, I. H.**, Zhang, J., Heilman, P.E., Hanafusa, H., Morse, S.S. Identification and Evaluation of new primer sets for the detection of lentivirus proviral DNA. *AIDS Res. Human Retrovir* 8:1981-1989, 1992.
10. Laurence, J., Siegal, F.P., Schattner, E., **Gelman, I.H.**, Morse, S. Individuals with acquired immune deficiency without evidence for human immunodeficiency virus types-1, -2 by serology, culture, and DNA amplification. *Lancet* 340:273-274, 1992.
12. **Gelman, I.H.** and Hanafusa, H. src-Specific immune regression of rous sarcoma virus-induced tumors. *Cancer Res* 53:915-920, 1993.
13. Bohensky, R.A., Papavassiliou, A.G., **Gelman, I.H.**, Silverstein, S. Identification of a promoter mapping within the reiterated sequences that flank the Herpes Simplex Virus type 1 UL region. *J Virol* 67:632-642, 1993.
14. **Gelman, I.H.**, Khan, S., Hanafusa H. Morphological transformation, tumorigenicity, and src-specific CTL-mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristoylated N-terminal domains. *Oncogene* 8:2995-3004, 1993.
15. Frankfort, B. and **Gelman, I.H.** Identification of novel cellular genes transcriptionally suppressed by v-src. *BBRC* 206:916-926, 1995.
16. Lin, X., Nelson, P., Van Tuyl, A., Johnson, R., **Gelman, I.H.** Isolation and characterization of a novel mitogenic regulatory gene, 322, which is transcriptionally suppressed in src- and ras-transformed cells. *Mol Cell Biol* 15(5):2754-2762, 1995.

17. Lin, X., Tombler, E., Nelson, P., Ross., M., **Gelman, I.H.** A Novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. *J Biol Chem* 271(45):28430-28438, 1996.
18. Lin, X., and **Gelman, I.H.** Re-expression of the major protein kinase C substrate, SSeCKS, suppresses v-src induced morphological transformation and oncogenic growth. *Cancer Res* 57(11):2304-2312, 1997.
19. Nelson, P. and **Gelman, I.H.** Cell-cycle regulated expression and serine phosphorylation of the myristylated protein kinase C substrate, SSeCKS: Correlation with cell confluency, G0 phase and serum response. *Molec Cell Biochem* 175:233-241, 1997.
20. **Gelman, I.H.**, Lee, K., Tombler, E., Gordon, R., Lin, X. Control of cytoskeletal architecture by the src-suppressed c kinase substrate, SSeCKS. *Cell Motil Cytoskeleton* 41(1): 1-17, 1998.
21. Nelson, P., Moissoglu, K., Vargas, J., Jr., Klotman, P.E., **Gelman, I.H.** The protein kinase C substrate, SSeCKS, controls actin-based stellate morphology in mesangial cells. *J Cell Sci.* 112:361-370, 1999.
22. **Gelman, I.H.**, Qiaoran X.I., Kumar C.C. Re-expression of the major PKC substrate, SSeCKS, correlates with the tumor suppressive effects of SCH51344 on Rat-6/src and Rat-6/ras fibroblasts but not on Rat-6/raf fibroblasts. *NY Acad Sci* 2999, 886:221-224.
23. **Gelman, I.H.**, Tombler, E., Vargas, J., Jr. developmental and tissue-specific expression of SSeCKS, a major PKC substrate with tumor suppressor activity, suggests roles in cytoskeletal architecture, formation of migratory processes and cell migration during embryogenesis. *Histochem J* 2000, 32:13-26.
24. **Gelman, I.H.**, Unger, E.R., Mawle, A., Nusenbaum, R., Reeves W.C. Chronic fatigue syndrome is not associated with the expression of endogenous retroviral p15E. *Mol Diagn* 2000, 5:155-156.
25. Lin, X., Nelson, P, **Gelman, I.H.** Regulation of G1->S progression by the SSeCKS tumor suppressor: control of cyclin d expression and cellular compartmentalization. *Molec Cell Biol* 2000, 20(19):7259-7272.
26. **Gelman, I.H.**, Lin, X., Nelson, P.J. SSeCKS controls G1->S progression by modulating cyclin D expression and cellular compartmentalization. *Molec Biol Cell* 11S:341a, 2000.
27. Cohen, S. B., Waha, A., **Gelman, I.H.**, Vogt, P.K., Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts. *Oncogene* 2001, 20:141-146.
28. Rombouts, K., Knittel, T., Wielant, A., Piscaglia, F., Machesky L., Hellemans K., **Gelman, I.**, Ramadori G., Geerts, A. Effect of Trichostatin A, a histone deacetylase inhibitor, on proteins of the actin cytoskeleton", in Cells of the Hepatic Sinusoid, E. Wisse, D.L. Knook, R. de Zanger, M.J.P. Arthur (Eds, The Kupffer Cell Foundation, The Netherlands, 2001, 8:271-273.
29. Wassler, M.J., Foote, C.I., **Gelman, I.H.**, Shur, B.D. Functional interaction between cell surface a-1,4-galactosyltransferase and SSeCKS, a PKC substrate. *J Cell Sci* 2001, 114:2291-2300.

30. Xia, W., Unger, P., Miller, L., Nelson, P.J., **Gelman, I.H.**, Suppression of prostate metastasis by re-expression of the Src-suppressed C kinase substrate, SSeCKS. *Cancer Res* 2001, 61:5644-5651.
31. Nelson, P.J., **Gelman, I.H.**, Klotman, P.E. Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinase promotes differentiation of infected podocytes. *J Am Soc Nephrol* 2001, 12:2827-2831.
32. Lin, X. and **Gelman, I.H.** Calmodulin and cyclin D anchoring sites on the Src-suppressed C kinase substrate, SSeCK. *Biochem Biophys Res Commun* 2002, 290:1368-1375.
33. Cara, A., Vargas, J., Jr., Keller, M., Jones, S., Mosoian, A., Gurtman, A., Cohen, A., Parkas, A., Wallach, F., Chusid, E., **Gelman, I.H.**, Klotman, M.E. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma viral HIV RNA. *Virology* 2002, 292:1-5.
34. Xia, W. and **Gelman, I.H.** Mitogen- and FAK-regulated tyrosine phosphorylation of the SSeCKS scaffolding protein modulates its actin-binding properties. *Exp Cell Res* 2002, 277(2):139-151.
35. Husain, M., Gusella, G.L., Klotman, M.E., **Gelman, I.H.**, Ross, M.D., Schwartz, E.J., Cara, A., Klotman, P.E. HIV-1 Nef induces anchorage-independent growth of cultured podocytes. *J Am Soc Nephrol* 2002, 13:1806-1815.
36. Rombouts, K., Knittel, T., Wielant, A., Piscaglia, F., Machesky, L., Hellemans, K., **Gelman, I.**, Ramadori, G., Geerts A. Actin filament formation, migration and contraction are impaired in hepatic stellate cells under the influence of trichostatin A, a histone deacetylase inhibitor. *J Hepatol* 2002, 37:788-796.
37. Nelson, P.J., Sunamoto, M., Husain, M., **Gelman, I.H.** HIV-1 expression induces cyclin D1 expression and activity in infected podocytes: a mechanism for the proliferative phenotype in HIV-associated nephropathy. *BioMed Central Microbiol* 2002, 2:26-36.
38. Sperber, K., Beuria, P., Singha, N., **Gelman, I.**, Cortes, P., Chen, H., Kraus, T. Induction of apoptosis by HIV-1 in infected monocytic cells. *J Immunol* 2003, 170:1566-1578.
39. Nelson, P.J., D'Agati, V., Gries, J.-M., Suarez, J.R., **Gelman, I.H.**, Amelioration of nephropathy in mice expressing HIV-1 gene by the potent cyclin-dependent kinase inhibitor, flavopiridol. *J Antimicrob Chemother* 2003, 51:921-929.
40. Lee, S.W., Kim, W.J., Choi, Y.K., Song, H.S., Son M.J., **Gelman, I.H.**, Kim, Y.J., Kim, K.W. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. *Nat Med* 2003, 9:900-906.
41. Moissoglu, K. and **Gelman, I.H.** v-Src rescues actin-based cytoskeletal architecture and cell motility, and induces enhanced anchorage-independence during oncogenic transformation of FAK-Null fibroblasts. *J Biol Chem* 2003, 278:47946-47959.
42. Gherardi, D., D'Agati, V.D., Chu, T.-H.T., Barnett, A., Gianella-Borradori, A., **Gelman, I.H.**, Nelson, P.J. Reversal of collapsing glomerulonephropathy in mice with the cyclin-dependent kinase inhibitor, CYC202. *J Am Soc Nephrol* 2004, 15:1212-1222.

43. Streb, J.W., Kitchen, C.M., **Gelman, I.H.**, Miano, J.M. Multiple promoters direct expression of the three AKAP12 isoforms with distinct subcellular and tissue distribution profiles. *J Biol Chem* 2004, 279:56014-56023.
43. Moissoglu, K., Sachdev, S and **Gelman, I.H.** Enhanced v-Src-induced oncogenic transformation in the absence of focal adhesion kinase is mediated by phosphatidylinositol 3-kinase. *Biochem Biophys Res Commun* 2005, 330:673-684.
44. Greenberg, R.S., Bernstein, A.M., Benezra, M., **Gelman, I.H.**, Taliana, L.D., Masur, S.K. FAK-dependent regulation of myofibroblast differentiation. *FASEB J* 2006, 20(7):1006-1018.
45. **Gelman, I.H.** and Gao, L. The SSeCKS/Gravin/AKAP12 metastasis suppressor inhibits podosome formation via RhoA- and Cdc42-dependent pathways. *Mol Cancer Res* 2006, 4(3):151-158. *Cover Photograph*
46. Su, B., Zheng, Q., Vaughan, M.M., Bu, Y., **Gelman, I.H.** SSeCKS metastasis-suppressing activity correlates with VEGF inhibition. *Cancer Res* 2006, 66(11):5599-5607.
47. Liu, Y. and **Gelman, I.H.** SSeCKS/Gravin/AKAP12 reprograms proliferative/angiogenic gene expression during suppression of v-Src-Induced oncogenesis. *BMC Cancer*, 2006, 6:105-117. PMID: PMC1463002.
48. Chaar, Z.Y., O'Reilly, P., **Gelman, I.H.**, Sabourin, L.A., v-src-dependent downregulation of the ste20-like kinase SLK by casein kinase II. *J Biol Chem* 2006, 281:28193-28199.
49. Bu, Y. and **Gelman, I.H.** v-Src-mediated downregulation of the SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1/Sp1/Sp3 complex. *J Biol Chem* 2007, 282(37):26725-39.
50. **Gelman IH.** AKAP12 (A kinase (PRKA) anchor protein 12). *Atlas Genet Cytogenet Oncol Haematol.* 2007;11(2):80-83.
51. Akakura, S., Huang, C., Nelson, P.J., Foster, B., **Gelman, I.H.** Loss of the *ssecks/gravin/akap12* gene results in prostatic hyperplasia. *Cancer Res* 2008, 68:5096-5103. PMID: PMC2839164
52. Lau G.M., Lau G.M., Yu G.L., **Gelman I.H.**, Gutowski A., Hangauer D., Fang J.W., Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro, *Dig Dis Sci* 2009, 54(7):1465-1474.
53. Song L., Ohnuma T., **Gelman I.H.**, Holland, J.F., Reovirus infection of cancer cells is not due to the activated Ras pathway. *Cancer Gene Therap* 2009, 16(4):382.
54. Sachdev S., Bu Y., **Gelman I.H.**, Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion. *BMC Cancer* 2009, 9:12-26. PMID: PMC2651180
55. Su, B., Bu, Y., Engelberg, D. and **Gelman, I.H.** "SSeCKS/Gravin/AKAP12 inhibits cancer cell invasion and chemotaxis by suppressing a PKC-Raf/MEK/ERK pathway". *J Biol Chem*, 2010, 285:4578-86. PMID: PMC2836062

56. Akakura, S., Nochajski, P., Gao, L., Sotomayor, P., Matsui, S.-I. and Gelman, I.H., "Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12", *Cell Cycle*, 2010, 9(23):4656-65. Cover photo. News and Views, "Unbearable stress: Collapse of the SSeCKS/AKAP12 scaffold leads to senescence and transformation", Hinds, P. *Cell Cycle*, vol. 10 (17), Sept. 1, 2011. PMID: PMC3048035
57. Bu, Y., Gao, L., **Gelman, I.H.**, "Role For Transcription Factor TFII-I in the Suppression of SSeCKS/Gravin/Akap12 Transcription By Src", *Int. J. Cancer*, 2011, 128(8):1836-42. doi: 10.1002/ijc.25524. PMID: PMC2997892.
58. Streb, J.W., Long, X., Lee, T.-H., Sun, Q., Kitchen, C.M., Georger, M.A., Slivano, O.J., Blaner, W.S., Carr, D.W., **Gelman, I.H.**, Miano, J., "Retinoid-Induced Expression and Activity of an Immediate Early Tumor Suppressor Gene in Vascular Smooth Muscle Cells", Submitted, *PLoS One*, 2011, 6(4);e18538. doi:10.1371/journal.pone.0018538. PMID: PMC3071728.
59. Akakura, S., Bouchard, R., Bshara, W., Morrison, C. and **Gelman, I.H.**, "Carcinogen-induced squamous papillomas and oncogenic progression in the absence of the SSeCKS/AKAP12 metastasis suppressor correlates with FAK upregulation", *Int. J. Cancer*, 2011, 129(8):2025-2031. PMID: PMC3107938.
60. Guo, L.-W., Su, B., Gao, L. and **Gelman, I.H.**, "Control of protein kinase C activity, phorbol ester-induced cytoskeletal remodeling and cell survival signals by the scaffolding protein SSeCKS/GRAVIN/AKAP12" *J. Biol. Chem.*, 2011, 286(44):38,356-38,366. PMID: PMC3207390.
61. Burnworth, B., Pippin, J., Akakura, S., Krofft, R., Zhang, G., Hudkins, K., Alpers, C.E., Smith, K., Shankland, S., **Gelman, I.H.**, and Nelson, P.J., "SSeCKS sequesters cyclin D1 in glomerular parietal epithelial cells", *Lab Invest.*, 2012, 92(4):499-510. **Impact factor = 3.828.**
62. Golubovskaya VM, Figel S, Ho BT, Johnson CP, Yemma M, Huang G, Zheng M, Nyberg C, Magis A, Ostrov DA, **Gelman IH**, Cance WG. A small molecule Focal Adhesion Kinase (FAK) inhibitor, targeting Y397 site: 1-(2-Hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1^{3,7}]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth *in vivo*. *Carcinogenesis*, 2012, 33(5):1004-1013. PMID: PMC3334519. **Impact factor = 5.815.**
63. **Gelman, I.H.**, "Missing Methods" in News and Opinion, *The Scientist*, <http://the-scientist.com/2012/05/03/opinion-missing-methods/>, May 3, 2012.
64. Ho, B., Olson, O., Figel, S., **Gelman, I.**, Cance, W., Golubovskaya, V. "Nanog increases Focal adhesion kinase (FAK) promoter activity and expression, and directly binds to FAK protein to be phosphorylated", *J Biol Chem*, 2012, 287(22)18656-73. PMID: PMC3365765. **Impact factor = 7.25.**
65. Su, B., Gao, L., Meng, F., Guo, L.-W., Rothschild, J., **Gelman, I.H.**, Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12. *Oncogene*, 2013, 32(16):2016-2026. PMID: PMC3449054. **Impact factor = 8.56.**

66. Liu, X., Yang, N., Figel, S.A, Wilson, K.E., Morrison, C.D., **Gelman, I.H.**, Zhang, J. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. *Oncogene*, 2013, 32(10):1266-1273. **Impact factor = 8.56.**
67. Havekes R, Canton DA, Park AJ, Huang T, Nie T, Day JP, Guercio LA, Grimes Q, Luczak V, **Gelman IH**, Baillie GS, Scott JD, Abel T. Gravin Orchestrates Protein Kinase A and β 2-Adrenergic Receptor Signaling Critical for Synaptic Plasticity and Memory. *J Neurosci*. 2012, 32(50):18137-49. doi: 10.1523/JNEUROSCI.3612-12.2012. Highlighted in: *The J Neurosci*, 32(50):18137-18149. PMID: PMC3533251. **Impact factor = 6.91.**
68. Smeets B, Boor P, Dijkman H, Sharma SV, Jirak P, Mooren F, Berger K, Bornemann J, **Gelman IH**, Floege J, van der Vlag J, Wetzels JF, Moeller MJ. Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration. *J Pathol*. 2013, 229(5):645-659. PMID: 3951144. **Impact factor = 7.33.**
69. Schulte, K., Berger, K., Boor, P., Jirak, P., **Gelman, I.H.**, Arkill, K.P., Neal, C.R., Kriz, W., Floege, J., Smeets, B., Moeller, M.J., Origin of Parietal Podocytes in Atubular Glomeruli Mapped by Lineage Tracing. *J Am Soc Nephrol*. 2014, 25(1):129-141. PMID:24071005. **Impact factor = 8.99.**
70. Su, B., Gillard, B., Gao, L., Eng, K.H., **Gelman, I.H.**, Src controls castration-recurrence of CWR22 prostate cancer xenografts. *Cancer Medicine*, 2013, 2(6):784-192. PMID: 3892383. **Impact factor = 2.84.**
71. Ko, H.-K. Akakura, S., Peresie, J., Goodrich, D.W., Foster, B.A., **Gelman, I.H.**, A transgenic model for early prostate metastasis to lymph nodes, *Cancer Research*, 2014, 74:945-953. PMID: 3892383. **Impact factor = 9.28. **4th most cited papers from Cancer Res. 2013-2014** (<http://cancerres.aacrjournals.org/reports/most-cited>).
72. Cha JH, Wee HJ, Seo JH, Ahn BJ, Park JH, Yang JM, Lee SW, Kim EH, Lee OH, Heo JH Lee HJ, **Gelman IH**, Ken Arai K, Lo EH, Kim KW, AKAP12 mediates barrier functions of fibrotic scars during CNS repair. *PLoS ONE*, 2014, 9(4):e94695. PMID: PMC3997571. **Impact factor = 3.53.**
73. Sheila Figel Dwyer and **I.H. Gelman**, Cross-phosphorylation and interaction between Src/FAK and MAPKAP5/PRAK in early focal adhesions controls cell motility, *J Cancer Biol Res.*, 2014, 2(1):1045.
74. Su, B., Gao, L., Baranowski, C., Gillard, B., Wang, J., Ransom, R., Ko, H.-K., **Gelman, I.H.** A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer, *PLoS ONE*, 2014, 9(7):e101411. PMID: PMC4077825. **Impact factor = 3.53.**
75. **Gelman, I.H.**, Peresie, J., Eng, K.H., Foster, B.A., Differential Requirement for Src-family Tyrosine Kinases in the Initiation, Progression and Metastasis of Prostate Cancer, *Molec. Cancer Res.*, 2014, 12(10):1470-9. PMID: PMC4201973. **Impact factor = 4.50.**
76. Jong-Ho Cha, Hee-Jun Wee, Ji Hae Seo, Bum Ju Ahn, Ji-Hyeon Park, Jun-Mo Yang, Sae-Won Lee, Ok-Hee Lee, Hyo-Jong Lee, **Irwin H. Gelman**, Ken Arai, and Eng Lo, Kyu-Won Kim, Prompt meningeal reconstruction mediated by oxygen-sensitive AKAP12 scaffolding protein after central nervous system injury, *Nature Commun*, 2014, 5:e4952. doi:10.1038/ncomms5952. **Impact factor = 10.74.**

77. **Irwin H. Gelman**, Beyond the Abstract: A transgenic mouse model for early prostate metastasis to lymph nodes, *Uro Today*, October 14, 2014, <http://www.urotoday.com/Prostate-Cancer/a-transgenic-mouse-model-for-early-prostate-metastasis-to-lymph-nodes-beyond-the-abstract-by-irwin-h-gelman-phd.html>
78. Ko, H.-K., Guo, L.-W., Su, B., Gao, L., **Gelman, I.H.**, Suppression of chemotaxis by SSeCKS via scaffolding of phosphoinositol phosphates and the recruitment of the Cdc42 GEF, Frabin, to the leading edge, *PLoS ONE*, 2014, 9(10):e111534. PMID: PMC4214753. **Impact factor = 3.53.**
79. Dwyer, S.F., Gao, L and **Gelman, I.H.**, Identification of Novel Focal Adhesion Kinase Substrates: Role for FAK in NFκB Signaling. *Int J Biol Sci*, 2015, 11(4):404-410. **Impact factor = 4.372.**
80. Hehnly, H., Canton, D., Bucko, P., Langeberg, L., Ogier, L., **Gelman, I.**, Santana, L., Wordeman, L., Scott, J. A mitotic kinase scaffold depleted in testicular seminomas impacts spindle orientation in germline stem cells, *eLife*, 2015, 4:e09384. **Impact factor = 9.322.**
81. Shourideh, M., Azabdaftari, G., Attwood, K., Depriest, A., Wadosky, K., Gillard, B., Karasik, E., Duncun, K., Heemers, H., Kyprianou, N., **Gelman, I.**, Corey, E., Vessella, R.L., Mohler, J.L., Koochekpour, S., GRM1 is an androgen-regulated gene and its expression correlates with prostate cancer progression in pre-clinical models. *Clin Cancer Res*, 2016 Jul 25. pii: clincanres.0137.2016. [Epub ahead of print]. **Impact factor = 8.738.**
82. Chattopadhyay, I., Wang, J., Qin, M., Gao, L., Holtz, R., Vessella, R.L., Leach, R.W., **Gelman, I.H.**, Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures. *Oncotarget*, 2017, 8(6):10,324-10,347. doi: 10.18632/oncotarget.14401. PMID: PMC5354662. **Impact factor = 5.008.**
83. Yang, J.M., Lee, H.S., Seo, J.H., Park, J.H., **Gelman, I.H.**, Lo, E.H., Kim, K.W. Structural environment built by AKAP12+ colon mesenchymal cells drives M2 macrophages during inflammation recovery. *Sci Rep*. 2017, 7:42723. doi: 10.1038/srep42723. PMID: PMC5311874. **Impact factor = 5.228.**
84. Zhang, Y., Shen, H., Withers, H., Yang, N., Denson, K.E., Mussell, A.L., Truskinovsky, A., Fan, Q., **Gelman, I.H.**, Frangou, C., Zhang, J., VGLL4 selectively represses YAP-dependent gene induction and tumorigenic phenotypes in breast cancer, *Sci. Reports*, 2017, 7(1):6190. PMID: PMC5522454. **Impact factor = 5.228.**
85. Muramatsu, M., Gao, L., Peresie, J., Balderman, B., Akakura, S., **Gelman, I.H.**, SSeCKS/Akap12 scaffolding functions suppress B16F10-induced peritoneal metastasis by attenuating Cxcl9/10 secretion by resident myofibroblasts, *Oncotarget*, 2017, 8(41): 70281–70298. PMID: PMC5642554. **Impact factor = 5.008.**
86. Maki, T., Choi, Y.K., Miyamoto, N., Shindo, A., Liang, A.C., Ahn, B.J., Mandeville, E.T., Kaji, S., Itoh, K., Seo, J.H., **Gelman, I.H.**, Lok, J., Takahashim, R., Kim, K.W., Lo, E.H., Arai, K., A-Kinase Anchor Protein 12 is required for oligodendrocyte renewal in white matter. *Stem Cells*, 2018, 36(5):751-760. PMID: PMC5918158. **Impact factor = 5.599.**
87. Smolinski, M.P., Bu, Y., Clements, J., **Gelman, I.H.**, Hegab, T., Cutler, D.L., Fang, J.W.S., Fetterly, G., Kwan, R., Barnett, A., Lau, J.Y.N., Hangauer, D.G., Discovery of Novel Dual

Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361), *J. Medicinal Chem.*, 2018, 61(11):4704-4719. PMID: 29617135. **Impact factor = 6.259.**

88. Fingleton B., Lange K., Caldwell B., Bankaitis K.V., **Gelman I.H.**; Board of the Metastasis Research Society, Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example. *Clin. Exp. Metastasis*, 2018, 34(8):443-447. PMID: 29484519. **Impact factor = 3.08.**
89. Muramatsu, M., Akakura, S., Gao, L., Peresie, J., Balderman, B., **Gelman, I.H.**, SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk. *Oncotarget*, 2018,9(71):33515-33527. PMCID: PMC6173366. **Impact Factor = 5.168.**
90. Mahpour, A., Smiraglia, D., Scruggs, B.S., Ouchi, T. **Gelman, I.H.**, A novel promoter element induces bidirectional transcription in the TATA-less CpG island-associated promoters, *PLoS One*, 2018, 13(10):e0205608. PMCID: PMC6192621. **Impact Factor = 2.766.**
91. Lee, H.S., Choi, J., Son, T., Lee, E.J., Kim, J.-G., Ryu, S.H., Lee, D., Jang, M.K., Yu, E., Chung, Y.-H., **Gelman, I.H.**, Kim, K-W, A-kinase anchoring protein 12 is downregulated in human hepatocellular carcinoma and its deficiency in mice aggravates thioacetamide-induced liver injury. *Oncol. Lett.*, 2018, 16(5):5907-5915. PMCID: PMC6176350. **Impact Factor = 1.554.**
92. McGrath, J., Panzica, L., Ransom, R., Withers, H.G., **Gelman, I.H.**, Identification of genes regulating breast cancer dormancy in 3D bone endosteal niche cultures, *Molec. Cancer Res.*, 2019, 17(4):860-869. PMCID: PMC6445695. **Impact factor = 4.597**
93. Zhang J., **Gelman I.H.**, Katsuta E., Liang Y., Wang X., Li J., Qu J., Yan L., Takabe K., Hochwald S.N., Glucose drives growth factor-independent esophageal cancer proliferation via phosphohistidine-FAK signaling, *Cell. Molec Gastroenterol Hepatol*, 2019, 8(1):37-60. PMID: 30836148.

PUBLICATIONS IN PRESS

1. Lingqiu Gao, Yahao Bu, David G. Hangauer, **Irwin H. Gelman**. Suppression of oncogenic proliferation by KX2-391, a novel inhibitor of Src-family tyrosine kinases. *Molecular Cancer Therapeutics.*, *in revision*. **Impact Factor = 5.365.**

PUBLICATIONS SUBMITTED

1. Park SI, Kopetz S, **Gelman I.H.**, Gallick GE. "A Novel Src Family Kinase Inhibitor (KX2-391) Targeting the Peptide Substrate-Binding Domain Inhibits Prostate Cancer Growth and Lymph Node Metastasis *in vivo*." Submitted *Molec Cancer Ther*.
2. Jun-Mo Yang , Hye Shin Lee , Ji-Hae Seo , Ji-Hyeon Park , **Irwin Gelman** , Eng Lo, Structural environment built by colon mesenchymal cells drives M2 macrophages during inflammation recovery. *Science Reports*, submitted.

3. Bing Su and **Irwin H. Gelman**, FOXO4 inhibits breast cancer cell invasion.
4. Poppinga, W., Elzinga, C., **Gelman, Irwin**, Heijink, I., Maarsingh, H., Meurs, H., Schmidt, M., AKAP12, not AKAP5, regulates β_2 -agonist-induced relaxation of tracheal smooth muscle. *British J Pharm.*, submitted.
5. Wilfred Poppinga, Laura Hesse, I. Sophie Bos, Sybrig de Vries, **Irwin Gelman**, Harm Maarsingh, Herman Meurs, Irene Heijink, and Martina Schmidt, AKAP5 and AKAP12 coordinate neutrophilia in a mouse model of pulmonary inflammation, *Am J Phys-Lung Cell Molec Phys*, submitted.

PUBLICATIONS IN PREPARATION

1. Ray, M., Zhang, S., Nochajski, P., Mohler, J., Marshall, J., **Gelman, I.H.** Loss of SSeCKS/Gravin/ AKAP12 staining predicts poor outcome in prostate cancer.
2. RNAi Screening Identifies A Novel Role for A-Kinase Anchoring Protein 12 (AKAP12) in B Cell Development and Function. Mutlu Kartal-Kaess, Luisa Cimmino, Simona Infantino, Mehmet Yabas, Jian-Guo Zhang, Laura Tuohey, **Irwin H. Gelman**, John D. Scott, Stephen L. Nutt, Anselm Enders, David Tarlinton and Ross A Dickins

BOOK CHAPTERS

1. Sudol S. and **Gelman, I.H.** The v-src oncogene and its signaling pathways. In: Atlas of Signal Transduction Eds: Bork, P, Margolis, B., Schleuning, W.D., Sudol, M. Walter DeGruyter and Company Publishers, Berlin and New York, 2001.
2. **Gelman, I.H.** Isolation of novel substrates using a tyrosine kinase overlay/in situ assay. In: Cancer Cell Signaling: Methods and Protocols, Ed: Terrian, D. Methods in Molecular Medicine, Humana Press, Inc., New Jersey, 2003.
3. Marius Sudol, **Irwin H. Gelman**, and Jianmin Zhang. YAP1 Uses Its Modular Protein Domains and Conserved Sequence Motifs to Orchestrate Diverse Repertoires of Signaling. Chapter 4, In: The Hippo Signaling Pathway and Cancer, Moshe Oren and Yael Aylon, Eds., Springer, NY, 2013, pp. 53-70.

INVITED PAPERS/REVIEWS

1. **Gelman, I.H.** Pathogenicity of AIDS-related Kaposi's sarcoma. *Oncol Rep* 2:321-324, 1995.
2. **Gelman, I.H.** Immunological and virological parameters of chronic fatigue syndrome. *Clin Immunol News* 15(8):100-104, 1995.
3. **Gelman, I.H.** Characterization of SSeCKS as a type II tumor suppressor. *Proc BACT* 4:1-14, 2001.

4. **Gelman, I.H.** The role of SSeCKS/Gravin/AKAP12 scaffolding proteins in the spatiotemporal control of signaling pathways in oncogenesis and development. *Front Biosci* 7:d1782-1797, 2002.
5. **Gelman, I.H.** Pyk 2 FAKs, any two FAKs. *Cell Biol. Int* 27:507-510, 2003.
6. **Gelman, I.** Hospitals must keep up with bioterrorism issues. *Healthcare Security Emergency Manag* 3(4):10-11, 2004.
7. **Gelman, I.H.** RNA interference (RNAi): Powerful gene discovery tool, potential therapeutic agent", *Nanotechnology Law Business* 3:2 2006.
8. **Gelman IH.** AKAP12. Atlas Genet Cytogenet Oncol Haematol. November 2006. URL: <http://AtlasGeneticsOncology.org/Genes/AKAP12ID607ch6q25>
9. **Gelman, I.H.** Metastasis suppression by SSeCKS/Gravin/AKAP12 gene through the spatiotemporal control of oncogenic signaling mediators. In: Molecular Basis of Metastasis, Eds. Rinker-Schaeffer, C., Sokoloff, M., Yamada, D. Humana Press 2007.
10. **Gelman, I.H.** Metastasis suppression by SSeCKS/Gravin/AKAP12 through the inhibition of distal angiogenesis, In: Developments in Metastasis Suppressors, Ed. Jackson, P., Nova Publications Australia, Chapt. XV, pp. 273-288, 2007.
11. **Gelman, I.H.** Metastasis suppression by SSeCKS/Gravin/AKAP12 through the spatiotemporal control of oncogenic signaling mediators. In: Adaptor Proteins and Cancer, Maria-Magdalena Georgescu, Ed., Transworld Research Network, Kerala, India, 2008, pp. 83-101.
12. **Gelman, I.H.** Src-family tyrosine kinases as therapeutic targets in advanced cancer. *Front. Biosci.* 2011, 3:801-807. PMID:21622091
13. **Gelman, I.H.** and Sudol, M., Introduction: Hanafusa Memorial Issue, Part 1. Guest co-Editor. *Genes and Cancer*, 2011, 1(11):1088.
14. **Gelman, I.H.** and Sudol, M., Introduction: Hanafusa Memorial Issue, Part 2. Guest co-Editor. *Genes and Cancer*, 2011, 1(12):1163.
15. **Gelman, I.H.**, Emerging roles for SSeCKS/Gravin/AKAP12 in the control of cell proliferation, cancer malignancy and barrierogenesis. *Genes and Cancer*, 2011, 1(11):1147-1156. PMCID: PMC3092279.
16. **Gelman, I.H.**, AKAP12 Molecular Page (A000239), Signaling Gateway, Nature Publications, February 18, 2011, <http://www.signaling-gateway.org/molecule/query?afcsid=A000239>
17. Figel, S. and **Gelman, I.H.**, Focal Adhesion Kinase Controls Prostate Cancer Progression Via Intrinsic Kinase and Scaffolding Functions, *Anticancer Agents Med Chem*, 2011, 11(7):607-616. PMID:21355844
18. **Gelman, I.H.**, Deconstructing the molecular mechanisms of cancer, *International Innovations*, 2011, 13:43-45.

19. Akakura, S. and **Irwin H. Gelman**, Pivotal role of AKAP12 in the regulation of cellular adhesion dynamics: control of cytoskeletal architecture, cell migration and mitogenic signaling. *J. Signal Transduction*, 2012, Article ID 529179. doi:10.1155/2012/529179. PMID: PMC3395252.
20. **Gelman, I.H.**, Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12, *Cancer Metastasis Rev.*, 2012, 31(3-4):493-500. doi: 10.1007/s10555-012-9360-1. PMC3908683. **Impact factor = 10.73.**
21. **Gelman, I.H.**, Androgen Receptor Activation in Castration-Recurrent Prostate Cancer: The Role of Src-Family and Ack1 Tyrosine Kinases, *Int J Biol Res*, 2014, 10(6):620-626. PMC4062955. **Impact factor = 4.37.**
22. **Gelman, I.H.**, AKAP12 card, *Atlas of Genetics and Cytogenetics in Oncology and Haematology* (<http://atlasgeneticsoncology.org/Genes/AKAP12ID607ch6q25.html>), updated 5/7/14.
23. **Gelman, I.H.**, How the TRAMP Model Revolutionized the Study of Prostate Cancer Progression, invited review, *Cancer Research*, 75th Anniversary Year Review Series. 2016, 76(21):6137-6139. **Impact factor = 8.556.**

INVITED LECTURES/POSTERS

- | | |
|-------------------|--|
| 1992 | Novel lentiviruses in Kaposi's sarcoma, The American Society for Virology, Ithaca, NY. |
| June 22, 1993 | V-src-encoded tumor regression antigens, American Association for Cancer Research, Orlando, FL |
| July 9-13-,1994 | Isolation and characterization of novel cellular genes transcriptionally suppressed in NIH3T3 fibroblasts transformed by the v-src oncogene. American Society for Virology 13 th Annual Meeting, Madison, WI |
| July 10-13, 1994 | Immunological and virological profile of chronic fatigue syndrome 6 th Annual American In-Vitro Allergy/Immunology Society, Boston, MA |
| March 19-25, 1995 | Identification and characterization of a novel regulatory/tumor suppressor gene, 322", American Association for Cancer Research, 86 th Annual Meeting, Toronto, Canada. |
| April 21-25, 1996 | SSeCKS is a novel src- and ras-suppressed substrate of Protein Kinase-C possibly involved in controlling actin-based cell shape or motility. American Association for Cancer Research 87 th Annual Meeting, Washington, DC
I.H. Gelman Co-Chair Session on Signal Transduction |
| April 25, 1996 | SSeCKS, a novel mitogenic regulator, Lecture at Brown University School of Medicine, Providence, RI. |

- June 18-21, 1996 Tumor suppression, growth arrest and regulation of cytoskeletal architecture by the src-suppressed pProtein Kinase C substrate SSeCK
12th Annual Oncogene Meeting, Frederick, MD
- October 30, 1996 Suppression of tumor formation via the control of cytoskeletal architecture,
Lecture at Wesleyan University, Department of Molecular Biology,
Middletown, CT
- February 19, 1997 Suppression of tumor formation via the control of cytoskeletal architecture
- Lecture at Harvard University, Department of Pathology, Cambridge, MA
- February 28, 1997 Suppression of tumor formation via the control of cytoskeletal architecture
- Lecture at The National Cancer Institute, Frederick, MD
- July 12, 1997 SSeCKS as a target for tumor diagnosis and suppression - Seminar at
Innovir, Inc., New York City, NY
- September 11, 1997 Tumor suppression, signaling and cytoskeletal control by SSeCKS, a
novel PKC and Src substrate with Kinase scaffolding activity. Seminar at
Schering-Plough, Inc., New Jersey
- March 30, 1998 Control of cytoskeletal architecture, cell cycle and tumorigenesis by the
src-suppressed C kinase substrate SSeCKS - Seminar at University of
California at Berkeley, Molecular and Cellular Biology Program
- September 13, 1998 Therapeutic model for prostate cancer: targeting the novel tumor.
suppressor, SSeCKS. CaP CURE 5th Annual Scientific Meeting, Lake
Tahoe, CA
- December 13, 1998 Control of G1→S phase transition by the tumor suppressor, SSeCKS.
Invited lecture, Exelixis Pharmaceuticals, Inc., San Francisco, CA
- June 27-30, 1999 The focal adhesion kinase, FAK, modulates cytoskeletal reorganization
during v-src-induced oncogenic transformation Cancer Research
Campaign, Beatson International Cancer Conference, Invasion and
Metastasis, Glasgow, Scotland
- July 2, 1999 Tumor suppression, control of mitogenesis and cytoskeletal architecture
by SSeCKS, a major PKC substrate with scaffolding activity University of
Mainz, Frankfurt, Germany
- October 22, 1999 A novel tumor suppression pathway: control of cyclin d expression and
compartmentalization by the src-suppressed C kinase substrate, SSeCKS.
Picower Institute, NY. Invited Seminar
- December 15, 1999 Suppression pathway: Control of cyclin D expression and
compartmentalization by the src-suppressed c kinase substrate, SSeCKS.
Moffitt Cancer Center, Tampa, FL. Invited Seminar
- December 11-15, 1999 A novel tumor suppression mechanism: Control of cyclin D expression and
compartmentalization by the Src-Suppressed C Kinase Substrate,

SSeCKS 39th Annual ASCB Meeting, Washington, DC. Poster Presentation

- March 21, 2000 Tumor suppression, control of mitogenesis and cytoskeletal architecture by SSeCKS, a Major PKC substrate with scaffolding activity. Hoffman-La Roche, Invited Seminar.
- April 1-5, 2000 Co-Chair, Signal Transduction Poster Discussion Session, 91st Annual Meeting, American Association for Cancer Research, San Francisco, CA
- May 10-12, 2000 Meeting Organizer, "Roles of protein tyrosine phosphorylation in signal transduction- The 25th anniversary of the c-Src discovery", May 10-12, 2000 in Osaka, Japan.
- October 11-16, 2000 Phosphorylation of the C-terminal cytoplasmic portion of polycystin-1 by focal adhesion kinase H.P. Li, C. Burrow, I.H. Gelman, P. Wilson 33rd Annual Meeting of the American Society of Nephrology. Toronto, Canada
- December 8-13, 2000 SSeCKS, a major PKC substrate with tumor suppressor activity, regulates G1->S progression by controlling the expression and cellular compartmentalization of cyclin D. ASCB 40th Annual Meeting, San Francisco, CA.
- March 9, 2001 Inhibition of prostate cancer metastasis by SSeCKS, a src- and ras-suppressed kinase scaffolding protein - New York Medical College Invited Seminar
- March 12, 2001 Inhibition of prostate cancer metastasis by SSeCKS, a src- and ras-suppressed kinase scaffolding protein - CUNY School of Medicine New York Invited Seminar
- March 24-28, 2001 Enhanced v-Src-induced oncogenic transformation in the absence of the focal adhesion kinase, FAK: FAK modulates activation of phosphatidylinositol 3-kinase", 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA
- March 24-28, 2001 Suppression of prostate cancer metastatic potential by the forced re-expression of Src-Suppressed C Kinase Substrate, SSeCKS: Evidence for tumor suppressor activity. 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA
- May 11, 2001 Enhanced v-Src-induced transformation in FAK-null cells through phosphatidylinositol 3-kinase dependent pathways. Osaka Biomedical Institute, Osaka, Japan
- May 12, 2001 Tumor suppression by the SSeCKS scaffolding protein 14th Annual BACT Symposium, Nagoya, Japan Invited Seminar
- May 15, 2001 Enhanced v-Src-induced transformation in FAK-null cells through phosphatidylinositol 3-kinase-dependent pathways. National Cancer Institute, University of Tokyo, Japan.

November 14, 2001	Science of bioterrorism, in shedding some light in the aftermath of September 11th, Symposium at Queens College, New York
December 12, 2001	Enhanced v-Src-induced transformation in FAK-null cells through phosphatidylinositol 3-kinase-dependent pathways 41 st Annual American Society for Cellular Biology Meeting, Washington, DC
December 4, 2001	Tumor suppression by the SSeCKS scaffolding protein Case Western Reserve Medical School, Ohio Invited Seminar
March 8, 2002	SSeCKS, a major PKC substrate with tumor suppressor and Kinase scaffolding activity, regulates G1->S progression by controlling the expression and cellular compartmentalization of cyclin D. Keystone Symposium, "Protein Phosphorylation and Mechanisms of Cellular Regulation", Taos, New Mexico
March 18, 2002	Tumor suppression by the SSeCKS/Gravin protein family through the spatiotemporal scaffolding of G1->S phase signaling proteins. Medical College of Georgia, Invited Seminar
April 6-10, 2002	FAK plays both positive and negative modulatory roles in v-Src-induced oncogenesis 93 rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA
April 17, 2002	SSeCKS/Gravin/AKAP12: A Novel Suppressor of v-Src and Ras-Induced Oncogenesis. Finch University of Health Sciences, The University of Chicago Medical School, Chicago, IL
May 20, 2002	Tumor suppression by the SSeCKS/Gravin protein family through the spatiotemporal scaffolding of G1->S phase signaling proteins. Roswell Park Cancer Institute, Buffalo, NY
June 17, 2002	SSeCKS/Gravin/AKAP12: A Novel Suppressor of v-Src and Ras-Induced Oncogenesis. Medical College of Wisconsin, Milwaukee, WI
September 30, 2002	Tumor suppression by the SSeCKS/Gravin protein family through the spatiotemporal scaffolding of G1->S phase signaling proteins. Hahneman Medical School, Philadelphia, PA
June 2003 -	Sept. 2004 Tumor suppression by the SSeCKS/Gravin protein family through thespatiotemporal scaffolding of G1->S phase signaling proteins. Internal seminars at Roswell Park Cancer Institute in the Departments of Molecular Therapeutics, Pharmacology, and Immunology
November 18, 2004	SSeCKS/Gravin/AKAP12-induced anti-angiogenesis in the suppression of prostate cancer metastasis Osaka Biomedical Institute, Osaka, Japan
February 3, 2005	The metastasis-suppressor function of SSeCKS/Gravin/AKAP12 in a prostate cancer model correlates with anti-angiogenesis. University of Miami School of Medicine, Miami, FL

March 29, 2005	The metastasis-suppressor function of SSeCKS/Gravin/AKAP12 in a prostate cancer model correlates with anti-angiogenesis. MD Anderson Cancer Center, Houston, TX
December 21, 2005	The metastasis-suppressor function of SSeCKS/Gravin/AKAP12 in a prostate cancer model correlates with anti-angiogenesis. University of Rochester School of Medicine, Rochester, NY
September 2-6, 2006	SSeCKS metastasis-suppressing activity correlates with angiogenesis inhibition. The 11 th International Congress of Metastasis Research Society, Tokushima, Japan
November 9-12, 2006	Control of metastatic neocascularogenesis by SeCKS/Gravin/AKAP12. 4 th International Meeting on Oncogenes: Benchtop to Bedside, Osaka, Japan
January 8, 2007	RNAi Libraries: A Powerful 'Omics' Dissection Tool", Metabonomics Research Day, State University of New York at Buffalo, Buffalo, NY
February 8-9, 2007	Control of metastatic neocascularogenesis by SeCKS/Gravin/AKAP12. Marshall University School of Medicine, Huntington, WV
September 5-7, 2007	The role of the SSeCKS/GRAVIN/AKAP12 gene in prostate cancer progression, metastasis and neovascularization, Innovative Minds in Prostate Cancer Today (IMPACT) Meeting, Atlanta, GA
October 11-13, 2007	Control of prostate tumor and metastatic progression by SSeCKS/Gravin/AKAP12 scaffolding functions. 14 th Annual Retreat, Prostate Cancer Foundation, Lake Tahoe, NV
April 12-16, 2008	Loss of ssecks/gravin/akap12 gene results in prostatic hyperplasia. 99 th Annual Meeting of the American Association for Cancer Research, San Diego, CA
April 12-16, 2008	Cytokinesis defects, polyploidy and premature senescence in SSeCKS/Gravin/AKAP12-null mouse embryo fibroblasts. 99 th Annual Meeting of the American Association for Cancer Research, San Diego, CA
April 12-16, 2008	KXO1 (KX2-391), a Src-family kinase inhibitor targeting the peptide-binding domain, suppresses oncogenic proliferation <i>in vitro</i> and <i>in vivo</i> . 99 th Annual Meeting of the American Association for Cancer Research, San Diego, CA
April 12-16, 2008	A role for the General Transcriptional Factor II -I (TFII-I) in Src-mediated transcriptional suppression of SSeCKS/Gravin/AKAP12 99 th Annual Meeting of the American Association for Cancer Research, San Diego, CA
August 4-7, 2008	SSeCKS/Gravin/AKAP12 suppresses metastases through tumor and microenvironment –specific pathways. Oral presentation and poster. Joint Metastasis Research Society – AACR Conference on Metastasis, Vancouver, BC, Canada

- April 15-20, 2009 Rb-dependent cellular senescence and G2/M checkpoint defects in cells lacking the metastasis suppressor, SSeCKS/Gravin/AKAP12. 100th Annual Meeting of the American Association for Cancer Research, Denver, CO.
- February 21-24, 2010 The SSeCKS/Gravin/AKAP12 metastasis suppressor inhibits prostate cancer cell chemotaxis and invasion by disengaging Src and scaffolding PKC-Raf/MEK/ERK. The Miami 2010 Nature Winter Symposium: Targeting Cancer Invasion and Metastasis. Miami, FL
- April 14 -19, 2010 Suppression of prostate cancer growth by the Src signaling inhibitor, KXO1 (KX2-391). 101th Annual Meeting of the American Association for Cancer Research, Washington, DC
- September 12-15, 2010 Roles for Tumor- and Stroma-Encoded SSeCKS/AKAP12 in Suppressing Metastasis. Shin Akakura, Bing Su, Yahao Bu and **Irwin H. Gelman**, AACR-Metastasis Research Society Conference on Metastasis and the Tumor Microenvironment. Philadelphia, PA.
- October 27-30, 2010 Small molecule drugs targeting the main autophosphorylation site (Y397) of Focal Adhesion Kinase are effective in suppressing tumorigenic growth. With Vita Golubovskaya. American Association for Cancer Research meeting Colorectal Cancer from Biology to Therapy, Philadelphia, PA.
- December 10-13, 2010 SSeCKS/AKAP12 prevents polyploidy/multinucleation and Rb-dependent cellular senescence by attenuating PKC activation. Shin Akakura, Peter Nochajski, Lingqiu Gao, Paula Sotomayor, Sei-ichi Matsui and **Irwin H. Gelman**, Meeting on Aging and Senescence, Cold Spring Harbor, NY.
- March 9-12, 2011 IDENTIFICATION OF NOVEL PROSTATE CANCER METASTASIS-SUPPRESSOR GENES USING GENOMIC RNA-INTERFERENCE SCREENS, Bing Su, Catherine Baranowski, **Irwin H. Gelman**, DOD IMPaCT Meeting, Orlando, FL.
- March 9-12, 2011 Role of Src-Family Kinases in the Progression to Castration Recurrent Prostate Cancer, Bing Su, Wendy Huss, Barbara Foster, Mike Moser, Gary Smith, James Mohler, **Irwin H. Gelman**, DOD IMPaCT Meeting, Orlando, FL.
- April 12-16, 2011 A loss-of-function shRNA library screen for the cell invasion-suppressing genes in LNCaP prostate cancer cells. Bing Su, Catherine Baranowski, **Irwin H. Gelman**, American Association for Cancer Research, Orlando, FL.
- May 26-27, 2011 Novel small molecule compounds targeting the main autophosphorylation site (Y397) of Focal Adhesion Kinase are effective to inhibit colon cancer growth. Golubovskaya V.M., Figel S., Ho B.T, Johnson C.P., Yemma M., Nyberg C., Ostrov D.A., **Gelman I. H.** and Cance W.G., 6th Protein Kinases in Drug Discovery, Boston, MA.

- August 3, 2011 Suppression of prostate cancer metastasis by SSeCKS/AKAP12, a PKC and Src scaffolding protein. Seminar at University of Washington, Department of Urology. Sponsor: Peter Nelson, M.D.
- August 4, 2011 Suppression of prostate cancer metastasis by SSeCKS/AKAP12, a PKC and Src scaffolding protein. Seminar at Fred Hutchison Cancer Institute, Seattle, WA. Sponsor: Carla Grandori, Ph.D.
- February 6, 2012 The combined loss of SSeCKS/Gravin/AKAP12 and Rb in the prostate promotes spontaneous lymph node metastases with basal-luminal transitional phenotypes, Hyun-Kyung Ko, Shin Akakura, Jennifer Peresie, Barbara Foster, **Irwin H. Gelman**, American Association for Cancer Research 2nd Bi-Annual Meeting Prostate Cancer, Orlando FL.
- April 4, 2012 AKAP12/SSeCKS suppresses peritoneal metastasis by regulating chemokine production, Shin Akakura, Masashi Muramatsu, Hyun-Kyung Ko, **Irwin H. Gelman**, Abstract #3429, American Association for Cancer Research, Denver, CO.
- June 25, 2012 Metastasis suppression mechanisms by the SSeCKS/Gravin/AKAP12 scaffolding protein. **Irwin H. Gelman**, Shenzhen PKU-HKUST Medical Center, China.
- August 23-25, 2012 Tumor Microenvironment GCRC International Symposium, Dept. of Pharmacy, Seoul National Univ. Seoul, Korea. **Irwin H. Gelman**, Suppression of Tumor and Metastasis Progression through the Scaffolding Functions of SSeCKS/Gravin/AKAP12.
- November 9, 2012 Collaborative Science Workshop, RPCI-Wilmot Cancer Center, University of Rochester, **Irwin H. Gelman**, Genomics of the Neoplastic Progression of Barrett's Esophagus.
- December 8-11, 2012 RNAi Screening Identifies A Novel Role for A-Kinase Anchoring Protein 12 (AKAP12) in B Cell Development and Function. Mutlu Kartal-Kaess, Luisa Cimmino, Simona Infantino, Mehmet Yabas, Jian-Guo Zhang, Laura Tuohey, **Irwin H. Gelman**, John D. Scott, Stephen L. Nutt, Anselm Enders, David Tarlinton and Ross A Dickins, 54th ASH Annual Meeting, Atlanta, GA.
- January 11-12, 2013 Targeting Tyrosine Kinases in Castration-Recurrent Prostate Cancer. Lecture, 3rd Annual RPCI-GU Retreat, Niagara Falls, NY.
- April 12, 2013 Transgenic model for early prostate metastasis to the lymph nodes, AACR Annual Meeting, Hyun-Kyung Ko, Shin Akakura, Jennifer Peresie, David W. Goodrich, Barbara A. Foster, Irwin H. Gelman
- November 12, 2013 The SSeCKS/Gravin/AKAP12 Scaffolding Protein Regulates Formation of the Pre-Metastatic Niche, Department of Biochemistry, SUNY at Buffalo.
- Oct. 22-26, 2014 Control of metastatic niche formation by Src-SSeCKS yin-yang regulation. 15th International Union of Biochemistry and Molecular Biology Meeting, Taipei, Taiwan. Invited speaker.

- October 26, 2014 Role of Src-family kinases in prostate tumor and metastasis formation. International Meeting on Advanced Cancer Biology, Nagoya, Japan. Invited speaker.
- November 11, 2014 The role of Src-family kinases in metastatic progression, Vermont Cancer Center Grand Rounds / Dept of Pharmacology, Burlington, VT
- October 11-15, 2015 Metastasis promotion: control of the Src/STAT-regulated senescent stromal secretome by SSeCKS/AKAP12 scaffolding protein, invited speaker, 7th International Meeting on Tumor Microenvironment, Tel Aviv, Israel.
- November 20-24, 2015 Transgenic model for early prostate cancer metastasis to the lymph nodes, AACR- Metastasis Meeting, Austin, TX; poster presentation.
- February 22-25, 2016 Novel Breast Cancer Enhancer Activity Maps Identified by STARR-seq Keystone Meeting on Enhancer Malfunction in Cancer, Santa Fe, NM
Transgenic models for prostate cancer indolence vs. malignant progression, Virginia Commonwealth University Massey Cancer Center.
- September 16-21, 2016 Src promotes castration-recurrent metastatic prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures, Indranil Chattopadhyay, Jianmin Wang, Maochun Qin, Lingqiu Gao, Renae Holtz, Robert L. Vessella, Robert W. Leach, **Irwin H. Gelman**. Metastasis Research Society Biennial Meeting, Chengdu, China.
- March 31, 2017 Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures, seminar Institute of Cellular and Molecular Biology- A*STAR.
- April 2, 2017 The role of the kinase scaffolding protein, SSeCKS/Gravin/AKAP12, in controlling Src-mediated oncogenic signaling and prostate cancer metastatic progression, seminar at National University of Singapore.
- May 30, 2017 Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures, seminar at IBM-Watson campus, Yorktown Heights, NY.
- July 28, 2017 Finding and forming new collaborations with team science. RPCI Annual Science Retreat, Ellicottville, NY.
- October 9, 2017 Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures, RPCI-CCSG Genetics Retreat, Buffalo, NY.
- October 11, 2017 Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures, poster, 2nd BNMC Translational Genomics & Epigenomics Symposium, Buffalo, NY.

November 28, 2017 Control of the Metastatic Niche by SSeCKS/AKAP12 Scaffolding Functions: Attenuation of CXCL9/10 secretion by resident fibroblasts, Oral presentation, European Association for Cancer Research Meeting on Seed and Soil, Berlin, Germany.

June 19-22, 2018 Identification of breast cancer dormancy-reactivation suppressor genes using a genomic shRNA screen. AACR Cancer Dormancy and Residual Disease Meeting, Montreal, QC, Canada

January 24, 2019 Keynote Address: Mechanisms and Susceptibilities of Metastatic Progression. 2019 SUNY-Buffalo Biological Sciences Symposium.

March 16-21, 2019 SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk. Poster presentation. Keystone Symposium on Metastasis and Metabolism, Florence, Italy.

June 6-8, 2019 Essential gene screens and how to discover genes and pathways that control dormancy. PCORI 2019 Conference on Metastatic Cancer Research Priorities, Univ. of North Carolina.

STUDENTS TRAINED

Graduates Students

Current

Karina Miller Grad. Student: 9/1/14 –
Characterization of the nuclear egress domain in the SSeCKS/AKAP12 metastasis suppressor

Seamus Degan Graduate Student: 9/18 –
Role of Sik2 kinase in promoting prostate cancer progression through the downregulation of *SMAD4*.

Past

Henry Withers Masters: 1/11 – 12/11; Grad. student: 1/12-4/18
Identification and characterization of novel metastasis genes in breast cancer

Louis Panzica Masters Student- 6/15 – 6/16
Characterization of genes regulating metastatic progression in the bone microenvironment
Current affiliation: SUNY at Buffalo School of Law, Sterne Kessler Goldstein & Fox law firm

Julie McGrath Masters Student- 9/13 – 8/15
Genomic shRNA screen to identify genes regulating metastatic progression in the bone microenvironment
Current affiliation: Ph.D. Program, Dept. of Molecular Biology, Arizona State University

David van Bruggen CanSys Masters student- 9/13-6/14
The Role of FAK phosphorylation of Prdx1 in cell survival
Current affiliation: Ph.D. Program, University of Leiden, Netherlands

Bruno Filipe Rodrigues Dos Santos CanSys Masters student- 6/12-6/13
The Role of FAK phosphorylation of PCDC6 in cell survival
Current affiliation: Ph.D. Program, University of Luxembourg

Hyun Kyung Ko Graduate Student - 9/08 – 5/13
RPCI/UB Dept. of Cell Stress Biology
Control of AKT-mediated oncogenesis by SSeCKS
Current affiliation: Postdoctoral fellow, Cleveland Clinic, Sharifi Lab

Sheila Figel Graduate Student – 2/10 – 6/13
RPCI/UB Dept. of Cellular and Molecular Biology
Characterization of novel FAK substrates in oncogenesis
Postdoctoral fellow: under Michael Ciesielski, Ph.D., RPCI

Yahao Bu Graduate Student - 6/03- 8/07
RPCI/UB Department of Cellular and Molecular Biology
SSeCKS/Gravin promoter elements that mediate downregulation by v-Src and in prostate cancer cells and SH3 Scaffolding domains in SSeCKS and their binding partners.
Current affiliation: Senior Scientist, Kinex Pharmaceuticals, LLC.

Ryan Ransom Masters Student – 9/10 – 7/12
Identification and characterization of novel metastasis genes in prostate cancer

Emily Malinowski CanSys Masters Student – 1/11 – 12/11
Androgen receptor binding sites in castration-recurrent prostate cancer by ChIP-seq
Current affiliation: Physician Assistant Program, Salus University

Rene Bouchard Masters Student – 9/08 – 2/10
RPCI/UB Dept. of Cellular and Molecular Biology
Characterization of novel FAK substrates in oncogenesis
Current Affiliation: Science Teacher, Nichols School, Buffalo, NY

Peter Nochajski Masters Student - 9/06-6/08
RPCI/UB Dept. of Cellular and Molecular Biology
Dysfunctional mitogenic and cytokinetic signaling leading to premature senescence and tetraploidy in SSeCKS-null cells.

Eugene Tombler CMBS Graduate Student - 9/96-8/02
Characterization of the genomic and promoter structure of SSeCKS.
Current Affiliation: Medical Director, Oncology at Medicom Worldwide, Inc. .

Kostas Moissoglu Graduate Student - 5/97-8/02
FAK-dependent pathways involved in v-src-induced oncogenic transformation.
Current Affiliation: Staff Scientist, National Cancer Institute, Lab of Cell & Developmental Signaling

Jesus Vargas, Jr. Graduate Student - 9/96-03
Developmental and tissue-specific expression of SSeCKS.
Role-Graduate Committee Member.
Current Affiliation: Medical Resident, AtlantiCare Medical Center, Pomona, NJ

Laura Gillim-Ross Graduate Student - 9/96-03
Sustained 2-LTR HIV-1 circles in macrophages in HIV-infected patients on HAART with low to undetectable viral loads. Role, Co-Preceptor.
Current Affiliation: Supervisor, Public Health Microbiology and Serology at Colorado Department of Public Health and Environment

Wei Xia Graduate Student - 9/95-6/01
Tyrosine phosphorylation of SSeCKS by the focal adhesion kinase, FAK and Metastasis suppression by SSeCKS in a prostate cancer model.
Current Affiliation: Staff Senior Scientist, Genewiz, NY, NY.

Cori Jordan MSSM Medical Student - 11/98-2/99
Identification of FAK substrates
Current Affiliation: Surgeon, Fairview Hospital, Maple Grove, MN.

Jiaojiao Zhang Graduate Student - 6/91-6/93
Cis-acting elements in the collagen type Ia2 promoter responsive to transcriptional down-regulation by the v-src oncogene.
Current Affiliation: Instructor in Medicine, Massachusetts General Hospital.

Xueying Lin Graduate Student - 9/94-2/99
Mechanism of tumor suppression, mitogenic control and cytoskeletal organization by the PKC substrate, SSeCKS, Postdoctoral Fellow, Harvard University, under Dr. Morris White, Rosalyn Diabetes Center.
Current affiliation: Asst. Prof., Department of Biochemistry & Molecular Biology, Mayo Clinic, Rochester, MN.

Peter Nelson BioMedical Thesis Student MSSM - 5/94-5/97
Isolation and characterization of 322-binding genes using the yeast two-hybrid technique.
Current Affiliation: Associate Professor of Urology, Department of Medicine, University of Washington School of Medicine, Seattle, WA.

Postdoctoral Students

Current

Past

Jose Serruya, M.D. Postdoctoral Fellowship - 1/92-3/94
Search for novel lentiviruses in AIDS-associated Kaposi's sarcoma.
Current affiliation: Pediatric Neurology, Saint John Episcopal Hospital.

Qioran Xi, Ph.D. Postdoctoral Fellowship, 6/97-8/98)
Identification and characterization of novel mitogenic regulatory genes.
Current Affiliation: Principle Investigator, Tsinghua University, China

Peter Nelson, M.D. National Kidney Foundation Clinical Fellow
Mount Sinai Medical School - 9/00-03
Role of cyclins in podocyte dedifferentiation and proliferation in HIV-associated nephropathy
Current Affiliation: Associate Professor, Department of Medicine, University of Washington, Seattle, WA.

Mohammed Husain, Ph.D. 9/99-03

Identification of HIV-1-encoded gene products responsible for the podocyte hypertrophy in AIDS-associated nephropathy.

Current Affiliation: Research Assistant Professor, Mount Sinai School of Medicine.

Masaaki Sunamoto, Ph.D. 9/98-03

Mechanisms of SH3-mediated activation of Src tyrosine kinase family members by HIV-1-encoded Nef in podocyte proliferation.

Current Affiliation: Research Assistant Professor, Mount Sinai School of Medicine

Yongzhong Liu, Ph.D. Postdoctoral Fellow, RPCI - 9/03-12/04

Signaling pathways and differential gene regulation induced by SSeCKS during suppression of oncogenesis by v-Src or in prostate cancer.

Current Affiliation: Professor, State-Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiaotong University

Changhui Huang, Ph.D. Postdoctoral Fellow, RPCI - 6/03-6/05

Role of the SSeCKS gene product in mouse embryonic development.

Sanjay Sachdev, Ph.D. Postdoctoral Fellow, RPCI - 6/03-6/06

Control of Src-mediated metastatic behavior by the focal adhesion kinase, FAK.

Current Affiliation: Senior Scientist, India.

Li-Wu Guo, Ph.D. Postdoctoral Fellow, RPCI - 3/05-6/08

SSeCKS scaffolding functions and sequences for PKC and PKA.

Current Affiliation: Assist. Prof., Univ. of Arkansas, Little Rock, AR.

Adam Kisailus, Ph.D. Postdoctoral Fellow, RPCI - 3/04-09

Novel FAK substrates involved in motility and adhesion signaling

Current Affiliation: Assist. Dean of Education, RPCI, Buffalo, NY

Bing Su, Ph.D. Postdoctoral Fellow, RPCI - 9/03-3/12

Novel angiogenesis inhibition pathways by SSeCKS/Gravin.

Current Affiliation: Assoc. Prof., Key Lab of Translational Cancer Research, Xinxiang Medical University, Xinxiang, Henan, China

Shin Akakura, Ph.D. Postdoctoral Fellow, RPCI - 6/05-3/12

Role of the SSeCKS gene product in mouse embryonic development.

Current Affiliation: Assistant Professor, Frontiers in Bioscience Research Institute in Aging and Cancer, Irvine, CA

Indranil Chattopadhyay, Ph.D. Postdoctoral Fellowship – 6/11- 6/13

Genomic signatures of androgen receptor driven castration-recurrent prostate cancer

Current affiliation: Asst. Professor of Biology, Central University of Tamil Nadu, India.

Masashi Muramatsu, Ph.D. Postdoctoral Fellowship – 9/11-3/15

SSeCKS/AKAP12 control of metastasis through the expression of pro-inflammatory chemokines

Current Affiliation: Assist. Professor, Kumamoto University, Japan

SUNY at Buffalo Undergraduate Fellows

- 2013-2016 Benjamin Balderman, Class of 2016. Received the 2014 Dean's Conference Scholarship Award.
Current affiliation: SUNY at Buffalo School of Medicine
- 2011-2013 Julian Rothschild, Class of 2013. Current affiliation: Albert Einstein School of Medicine.

Summer High School Students

- 2012 Michelle Pagan, St. Joseph Hill Academy, Brooklyn, NY
- 2011 Jordan DeHoney- Canisius High School
- 2010 Peter Donnelly- Williamsville East High School
Nadav Newman- CHAT High School, Toronto, Canada; Current Affiliation:
University of Hamilton, Canada
- 2009 Richard Grey – Canisius High School, NCI-RPCI
- 2008 Kaitlin Skelton - Batavia High School, NCI-RPCI
- 2007 Sanjay Kumar - Batavia High School, NCI-RPCI ; Current Affiliation: SUNY Buffalo School of Medicine, Presidential Scholar
- 2006 Elliot Penna, Eden High School, NCI-RPCI
- 2005 Yuri Hanada, Albany High School, NCI-RPCI
Current Affiliation: undergraduate at MIT- bio-engineering research in the lab of Prof. Ioannis Yannas.
- 2004 Jared Gruszecki, Jericho High School, NCI-RPCI
Harvard University undergraduate starting in Sept. 2005.
Audrey Gelman, Bard High School Early College, New York University
- 1998-2000 Ariel Bulua, Horace Mann High School, B.A.- Yale University.
Current Affiliation: Resident in Pediatric Neurology at Mount Sinai School of Medicine. Clinical Research Training Fellowship at the NIH (2007-2008).
- 1996 Amy Wang, Stuyvesant High School, B.A- Harvard University, 2001
- 1995 Debra Wang, Stuyvesant High School
- 1994 Ralph Johnson, 1994, Martin Luther King High School.
Current Affiliation: Lawyer, New York City.
- 1993 Kathy Castellano, Hunter High School

Summer College Students

- 2018 Ngozi Elobuike, Howard University

2016 Reni Olu, Howard University

2015 Shannon Fox, James Madison University, VA

2013 Benjamin Balderman, SUNY at Buffalo

2012 Julian Rothschild, SUNY at Buffalo

2011 Mark Bucsek- SUNY Buffalo; Current Affiliation: SUNY Buffalo School of Medicine

2010 Zoe Welch- Haverford College
Catherine Baranowski- Skidmore; Current Affiliation: Harvard Graduate School of Arts and Sciences Ph.D. Program

2009 Julius Rothschild- SUNY Binghamton; SUNY Buffalo-Presidential Scholar.
Current Affiliation: Albert Einstein School of Medicine.

2008 Shruti Sevak, E. Michigan School of Medicine, NSF-RPCI

2007 Christine Szalinski, NSF-RPCI, SUNY-Geneseo.
Featured in the Buffalo News, <http://www.buffalonews.com/home/story/231629.html>

2006 Stephanie Matuszewski, NSF-RPCI, Rochester Institute of Technology.

Marijo Bilitski, Washington & Jefferson College (PA); sponsored by Kinex Pharmaceuticals, LLC

2005 Angela Long, University of Washington-Walla Walla, NSF-RPCI Summer

2004 Tiffany Williams, NCI-RPCI, University of Kentucky, Poster on SSeCKS shRNA affects on proliferation and cell motility selected to be presented in the Posters-at-the-Capitol poster conference, sponsored by the state of Kentucky's Senator and House of Representatives.

1999 Tara Lariat, Rudin-Sigma Xi Summer Fellow, Drew University
Current affiliation: Ph.D.student, Mount Sinai School of Medicine

1997 Seth Kurtz, Rudin-Sigma Xi Summer Fellow, CUNY-Queens College.

Maria Ocampo, Rudin-Sigma Xi Summer Fellow, Mount St. Mary's College, New York University Graduate School, Ph.D.
Current Affiliation: Postdoctoral Fellow, London Research Institute (Featured in THE SCIENTIST, Supplement November, 2006, page 34-35).

1996 Rostant Paul Farfan, Rudin-Sigma Xi Summer Fellow , Medgar Evers College. Current Affiliation: Troy State University.

1995 Wyndham Lathem, Rudin-Sigma Xi Summer Fellow, Vassar College

1993 Anna Van Tuyl, Rudin-Sigma Xi Summer Fellow, Amherst College; MD, SUNY Downstate School of Medicine

Current Affiliation: Medical Resident, North Shore-Long Island Jewish Hospital.

Thesis Committees

- 7/91 Xingqiang Li -Mutational analysis of the promoter required for influenza virus virion RNA synthesis.
- 5/92-10/94 Martin Lock - Molecular control of respiratory syncytial virus genome replication.
- 10/92-6/95 James Richardson -Cooperation of N and G proteins in respiratory syncytial virus transcription.
- 5/93 Yuan-Ping Han - Identification of substrates for the insulin receptor kinase from 12/94; 6/96 3T3-L1 adipocytes
- 5/93 Jing Chen - Generation of temperature-sensitive receptor protein tyrosine kinases and analysis of their signal transduction.
- 6/93 Shengwen Li - Expression and characterization of NP185, a synapse-specific and clatherin coated-vesicle associated protein.
- 8/93 Jianmin Chen - Structure, expression and function of chicken proto-oncogene c-ros
- 9/93 Delong Liu - Transforming activity of the IGF receptor gene product.
- 12/93; 5/95 Qinghua Xiong - Signal transduction of the c-ros proto-oncogene
- 1/94 Ruchika W. Gupta - Characterization of the effect of protein phosphatase 2A upon v-src-induced cell signaling.
- 6/94 H. Subbu Rao - Isolation of chromosome-specific DNA fragments.
- 8/94 Tom Kraus - Cloning of the BCSF cytokine gene.
- 5/95 Yixing Jiang - Cellular Substrates of ros Involved in Morphological Transformation
- 10/95 Marcello Curto -Hunter College - Generation of multiple intracellular signals by v-src
- 4/96 Dongquon Chen - The regulation and function of NF-IL-6 and pRb in B cell terminal differentiation.
- 4/96 Xueying Lin - Characterization of SSeCKS, a src-suppressed C kinase substrate involved in growth control and cytoskeletal architecture.
- 5/96 Vera Go - Identification and characterization of sequences differentially expressed in MCF-7 breast carcinoma cells upon induction with 17 α -estradiol.
- 6/96 Wenjun Zhang - Characterization of the EKLF promoter expression during erythropoiesis.
- 6/96 Amy Benedict

- 6/96 Jessica Feinleib - Reversion of ras-induced anchorage-independent growth by cyclin A.
- 12/96 Kira S. Ermekova - Ligands of FE65 WW Domain: Identification, characterization and possible function.
- 12/96 Ulrich Hermanto -The role of IGIP in RPTK-mediated signaling functions.
Thesis Defense (7/19/99): Signal Transduction by Insulin-like Growth Factor Receptor in normal and transformed cells, Committee Chair.
- 1/97 Jessica Feinleib -Cdo, a novel CAM related gene and its role in PC-12 neurite outgrowth.
- 1/97 Marcello Curto, Hunter College -Intracellular signals activated by the src oncoprotein.
- 3/97 Ellen J. Yang - The molecular role of Pw1 in relationship to muscle differentiation, apoptosis, TNF signaling and the cell cycle.
- 5/97 Ed Rashofsky - CMBS 2nd exam, general knowledge.
- 6/97 Julie Talon - Role of influenza viral NS2 protein in the nuclear export of viral RNPs
- 8/97 John Tullai - The role of phosphorylation in the regulation of endopeptidase EC 3.4.24.15.
- 12/97 Masako Osada - Transforming activity of a novel R-Ras gene
- 5/98 Jesus Vargas, Jr. - Attenuated integrase-defective HIV-1 viruses
- 6/98 Pallevi Sachdev - Transforming activity of the Insulin Receptor.
Thesis Defense (7/23/99) "Signal Transduction pathways mediating cellular transformation via an oncogenic human insulin-like growth factor-I receptor
- 6/98 Alex Chang - Isolation and Analysis of WW Domain Ligands in Yeast
- 7/98 Susan Cong - Transformation mechanisms of the ros oncogene
Thesis Defense Chair.
- 8/98 Nicola Campbell - The functional characterization of gp180, a novel CD8 ligand expressed by intestinal epithelial cells.
- 7/98 Lisa Pomerantz - MCBDS 2nd exam, general knowledge.
- 12/98 Dongquon Chen - Cell cycle control in B cell terminal differentiation induced by IL-6:
Repression of Epstein-Barr virus LMP1 by CDK inhibitor p18INK4C.
- 12/98 Maithao Le - MCBDS 2nd exam, general knowledge.
- 2/99 Jason Paragas - A proline-rich motif from the VSV M protein functions as a signal for virus-like particle formation.

- 10/00 M. Uttamsingh - Role of small Rho family GTPases in Ros-mediated oncogenic transformation.
- 11/00 Paul Lee - Control of kinase folding and activity by the chaperones Hsp90, Hsp70 and Cdc37.
- 12/00 John Tullai - Post-translational regulation of the neuropeptide processing enzyme EC 3.4.24.15.
- 6/01 Maithao Le - Small Rho family GTPases in IGFR signaling and oncogenesis.
- 11/01 Pallavi Sachdev -Role of Rho Family GTPases and their upstream regulator, Vav3, in signaling and cell transformation mediated by receptor protein tyrosine kinases. Committee Chairman.
- 6/02 Shoshana Greenberg - Role of FAK in control of smooth muscle actin expression and myofibroblast differentiation.
- 7/02 Roger Gutierrez - Albert Einstein College of Medicine, TKAP80 and SSeCKS in rat testicular development
- 9/02 Vanessa Roderik - Hunter College, PLD activation in breast cancer
- 12/04 Jeffrey Streb - University of Rochester, Alternately targeted isoforms and genetic expansion of A Kinase Anchoring Proteins increase signaling network potential.
- 6/07 Adebusola A. Alagbala - RPCI - Inhibition of prostate cancer progression by antagonizing the Vitamin D receptor
- 10/07 George Cheng - Mount Sinai Medical School - Role of TWIST in breast cancer invasiveness.
- 5/08 Shannon Morey – RPCI - Promoter methylation control in the TRAMP model.
- 6/08 Shangchiung Chen – RPCI - Plasminogen activator inhibitor-1 as a therapeutic agent.
- 8/08 Emre Dayanc - RPCI - Control of natural killer cell cytotoxicity by low-level hyperthermia
- 10/08 Jason Kirk – RPCI - Affect of microenvironment on prostate cancer metastasis
- 10/09 Anna Bianchi – RPCI- The role of integrin $\beta 5$ in the TGF- β -mediated EMT in normal and carcinoma cells
- 12/09 Michael Ray- RPCI Masters Thesis: “Evaluation of Manual and Automated Techniques in Segmentation of Digitized Prostate Tissue Microarray Cores”
- 8/13 Vineet Dhiman- RPCI- Promoter methylation dynamics controlling AR gene response
- 2/14 Yiyun Zhou, UB-Biochem- MAP Kinase pathways controlling Drosophila midphase formation

- 6/17 Michelle Limoge, RPCI C&MB, Role of TGFb/TNFa signaling induced by tumor fibroblasts in MMP9 production, breast tumorigenicity and metastasis
- 9/17 Trisha Dreslinski, RPCI-C&MB, AMPK signaling: novel control of contact inhibition
- 10/17 Samantha Sobus, RPCI-Pharmacology, Nicotine-regulated chemotherapy and radiation suppression pathways in lung cancer
- 11/17 Sheng-Yu Ku, RPCI-Prevention, Neuroendocrine transdifferentiation in prostate cancer progression
- 12/17 Mahamet Babagana, RPCI-Stress Biology, Identifying and Targeting Mechanisms of Resistance to BRAF Inhibitors
- 2/18 Amin Mahpour, RPCI-CGGD, The role of the CGCG element in the human genome
- 3/18 Kayla Wilson, RPCI, C&MB, Role of PTPN14 in YAP-mediated oncogenic transformation
- 5/18 Danielle Twum, RPCI-CI, IRF8 plays in macrophage polarization and repolarization
- 6/18 Henry Withers, RPCI-CGGD, Identification of novel metastasis suppressor genes by functional genomic screens in breast and prostate cancer.

CURRENT STUDENT COMMITTEES

<u>Student</u>	<u>Program</u>	<u>Mentor</u>	<u>Project</u>
Felicia L. Lenzo	CSSB	Kurenova	
Laura Prendergast	Stress Biology	Gurova	